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Thesis Summary  
Primary aldosteronism (PA) is the most common secondary cause of 
hypertension with a prevalence of about 10%. About half of PA cases are 
caused by aldosterone-producing adenomas (APA).  
Two APA subtypes, ZG-like and ZF-like APAs, have been described, 
according to the histological resemblance to normal adrenocortical zona 
glomerulosa (ZG) and zona fasciculata (ZF), underlying somatic mutations 
(KCNJ5 commonly found in ZF-like, CACN1AD, ATP1A1, ATP2B3, CTNNB1 
in ZG-like APAs), and transcriptome profile. It is unknown if the process of 
tumorigenesis differs between ZG- and ZF-like APAs. In order to define ZG-
specific genes, we have compared the transcriptome of APAs and their 
adjacent adrenal glands by microarray assay.  RNA was isolated by laser 
capture microdissection (LCM) from adjacent ZG, ZF and APAs from 14 
patients with Conn’s and 7 patients with phaeocromocytoma. Two top hit 
genes from the comparison of ZG vs ZF were functionally studied, ANO4 and 
NEFM. 
 
NEFM, encoding neurofilament medium, was the fourth most up-regulated 
gene in ZG vs ZF, showing 14.8-fold-fold higher expression levels (p=9.16-12) 
in ZG than ZF.  NEFM was also one of the most down-regulated genes in ZF-
like vs ZG-like APAs. Immunohistochemistry (IHC) confirmed selective high 
expression of NEFM in ZG and ZG-like APAs. 
 
Silencing NEFM in H295R cells increased aldosterone secretion and cell 
proliferation.  In addition, it increased stimulation and inhibition, respectively, 
of aldosterone secretion from H295R cells by the dopamine receptor D1R 
agonist fenoldopam and antagonist SCH23390.  
 
IHC showed predominantly intracellular staining for D1R in NEFM-rich ZG-like 
APAs, but membranous staining in NEFM-poor ZF-like APAs. Aldosterone 
secretion in response to fenoldopam in primary cells from ZG-like APAs was 
lower than in cells from ZF-like APAs. NEFM expression levels directly 
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correlate with KCNJ5 phenotype: KCNJ5 mutations down-regulate NEFM 
mRNA and protein levels in H295R cells and in primary cells from ZG-like 
APAs. 
 
ANO4, encoding a Ca2+-activated chloride channel family member, was the 
third most upregulated gene, showing 19.9-fold higher expression levels 
(p=6.6x10-24) in ZG than ZF.  IHC confirmed ZG selectivity of ANO4 protein in 
the adrenal cortex. The staining was mainly cytoplasmic. Unlike NEFM, there 
was no difference in expression of ANO4 between ZG- and ZF-like APAs, the 
levels being mid-way between those of ZF and ZG. 
 
Overexpression of ANO4 in H295R cells caused an increase in CYP11B2 and 
NR4A2 gene expression levels but basal aldosterone secretion was 
unchanged. In the presence of calcium agonists and aldosterone 
secretagogues, ANO4 reduced aldosterone secretion. ANO4 subcellular 
localisation was confirmed as cytoplasmic by immunofluorescence 
microscopy of transfected cells.  When exposed to calcium ionophores, ANO4 
generated only small chloride currents as detected by YFP assay. 
 
In summary, the comparison of whole transcriptome of ZG with their paired ZF 
found unexpected up-regulated genes. Most of the highly up regulated genes 
in human ZG, including NEFM and ANO4, inhibit either basal or stimulated 
aldosterone secretion, and this may reflect an adaptive response to chronic 
high salt intake.  
 
No clear-cut correspondence was found between transcriptome of APAs and 
their resembling zone of adrenal cortex. The down-regulation of NEFM 
following transfection of mutant KCNJ5 suggests that ZF-like properties may 
be a consequence of mutation, rather than tissue of origin. 
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Chapter 1 – Introduction  
1.1 Primary aldosteronism: a clinical overview 
Primary aldosteronism (PA) is the most common curable cause of arterial 
hypertension (HT).  This condition is defined as a state of increased secretion 
of aldosterone, autonomous of the renin–angiotensin system.   Dr. Jerome W. 
Conn described PA in 1955 (Conn 1955; Conn & Louis 1956).   
 
PA causes sodium and water retention and potassium loss eventually causing 
HT and hypokalaemia, but also cardiovascular and renal damage. 
It was Jerome Conn himself who, 10 years after describing the firs PA case, 
reported a series of PA cases in which PA with normokalaemia was the most 
frequent presentation, while severe cases with prolonged exposure to 
aldosterone excess had HT and low serum potassium levels.   
 
Despite these early reports, in most of the studies from the 1970s to early 
1990s PA was screened exclusively in hypokalemic patients, and this strategy 
consequently affected its prevalence estimation.  Most of the studies 
performed before the introduction of the aldosterone-to-renin-ratio (ARR) in 
1981 as a screening tool for PA reported a low prevalence (<1%) (Hiramatsu 
et al. 1981).  In the following years, the PA screening strategy based on the 
ARR in hypertensive patients (independently from potassium levels) has been 
used in several studies that, although showing different prevalence because 
of the use of different diagnostic criteria, found that PA is the commonest 
treatable cause of HT. 
 
The first prospective study, the Primary Aldosteronism Prevalence in 
Hypertensives (PAPY) study, was published only in 2006.  The PAPY Study 
showed that PA was present in about 11% of newly diagnosed consecutive 
HT patients referred to a third level HT centre.  About half of them, 4.8% of 
the overall studied patients, had a surgically treatable subtype, i.e. 
aldosterone producing adenomas (APAs) (Rossi et al. 2006). 
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The subtype differentiation is fundamental in PA diagnostic work-up, as 
patients could receive a specific treatment (adrenalectomy for the unilateral 
subtypes, mineralocorticoid receptor (MR) antagonists for those patients who 
are not suitable of surgery or with bilateral aldosterone excess).  
 
The high prevalence of PA in hypertensive populations represents a challenge 
in terms of planning a strategy of investigation and selection of patients in 
different public health systems.  Some centres prefer to screen all referred 
patients despite the costs, taking into consideration both the high prevalence 
of PA and its high rate of cardiovascular complications, while other centres 
address to the diagnostic work-up for PA only those subgroups of patients 
with an increased pre-test probability of having PA (resistant HT, significant 
target organ damage, young age, hypokalemia, early onset of stroke or HT, 
HT plus adrenal mass, family history of PA). 
 
Of note, the ARR, used as a screening test for PA, is affected by several 
factors, in primis most of the first-line anti-hypertensive medications, such as 
MR antagonists, beta-blockers, ACE Inhibitors, sartans, diuretics and 
dihydropyridinic calcium channel blockers.  According to the Endocrine 
Society guidelines, these medications should be stopped for at least four 
weeks and replaced by alpha-blockers and/or verapamil to control HT, but this 
is not always feasible in clinical practice.  Nevertheless, other 
noncardiovascular medications (as instance some anti-depressants) can 
influence both aldosterone and renin levels.  Some physiological factors 
should also be considered when interpreting the ARR, such as age and race 
(both afro caribbean and elderly patients are known to have low renin levels), 
orthostatism, water and salt intake, or different phases of menstrual cycle in 
women (Funder et al. 2016).  
1.1.1 PA Subtypes, differentiation and diagnosis 
Once the biochemical diagnosis of PA has been confirmed, the next steps 
and tests in the diagnostic workup aim at differentiating the PA subtypes.  
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As mentioned before, the purpose of subtype differentiation is mainly 
therapeutic and discriminates unilateral from bilateral adrenal aldosterone 
producing lesions, while excluding rare malignant and genetic forms. 
 
If the autonomous aldosterone production is unilateral, indication is given to 
homolateral adrenalectomy, which provides biochemical cure of PA in 100% 
of patients (if the pre-surgery diagnosis of unilateral disease was correct) and 
can either cure (in 40–80% of cases) or improve BP control in most of 
patients. 
 
Bilateral PA forms are treated medically with aldosterone antagonists as first 
choice (mainly spironolactone, eplerenone as MR antagonist and amiloride as 
epithelial sodium channel blocker).  Medical treatment does not affect the 
number of medications needed to achieve BP control target in most of 
patients. 
 
According to the Endocrine Society guidelines, MRI, CT or both should be 
performed in patients with PA with the main purpose of excluding an 
aldosterone-producing carcinoma and to study the anatomy of the adrenal 
veins in view of performing an adrenal vein sampling (AVS).   
A CT scan with 2–3 mm cuts is currently the best technique available for the 
detection of adrenal nodules, but here are some important caveats about 
adrenal imaging in PA:  a high percentage (about 40%) of APAs are <6 mm in 
diameter and hardly visible even with CT or MRI scan.  Moreover, not 
secreting adrenal nodules (or incidentalomas) are quite frequent in general 
population (especially over 40 years), and this obviously affects the sensitivity 
and specificity of adrenal imaging in the diagnosing unilateral PA. 
Even the discrimination of unilateral vs bilateral PA subtypes cannot rely on 
conventional adrenal imaging: a review found that, when compared to AVS as 
gold standard for the diagnosis, CT scans are misleading in about 50% of 
patients, giving false positive and false negative in 25% of the cases 
(Kempers et al. 2009).  
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In view of these evidences, the indication to adrenalectomy should not be 
decided on the basis of the imaging findings, but only after solid evidence of 
lateralisation of the aldosterone excess.  
 
AVS, as defined in the Endocrine Society guidelines, is instead the gold 
standard test to differentiate unilateral and bilateral causes. 
AVS is an invasive and expensive test, and patients should be prepared to in 
terms of modifications of antihypertensive therapy and correction of 
hypokalemia.  Moreover AVS has a considerable percentage of failure in 
selectivity due to difficulties in cannulising the right adrenal vein for its 
anatomy, even in the hands of an expert radiologist. 
Therefore, AVS should be performed only in patients with confirmed and 
unequivocal PA biochemical diagnosis, willing to have adrenalectomy and 
with no contraindications to general anesthesia.  All the likely, not surgically 
treatable causes of PA potentially diagnosable at this stage (such as familial 
PA type I) should be excluded before the patient undergoes AVS. 
1.1.2 PA treatment according to the subtypes 
In 100% of patients with unilateral PA adrenalectomy normalizes the 
biochemical pattern of PA (aldosterone-to renin ratio and potassium levels), 
improves BP control and target organ damage, reduces the number of anti 
hypertensive medications, but HT is cured in only 40% of cases.  Prediction of 
the surgical cure of HT has been HT with several clinical factors, as instance 
young age, shorter duration of HT, higher preoperative blood pressure; 
preoperative normal renal function, but none of the possible “scores” had 
been conventionally accepted in clinical practice (Rossi, 2011). 
PA patients with bilateral aldosterone overproduction or not willing to or 
unelegible to surgery, should be receive as first line medications that 
specifically inhibit aldosterone action. 
Side effects from overtreatment or high doses are volume depletion, pre-renal 
kidney failure, increased creatinine, and potentially severe hyperkalemia. 
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These drugs should therefore be used carefully, at minimum doses and with 
strict monitoring of potassemia and creatinine in patients with known renal 
failure, or taking other drugs affecting kidney function. 
Spironolactone blocks mineralocorticoid receptor as an agonist competitor.  
This drug has also inhibitory activity at the testosterone receptor and agonist 
activity at the progesterone receptor, therefore it can cause  sex-steroid-
related adverse effects, such as gynecomastia, loss of libido, menstrual 
irregularities, in a dose-dependent manner.  Eplerenone is a more selective 
MR antagonist with less action on sex-steroid receptors and consequently 
less side effects.  It is also indicated in children and pregnancy for the same 
reasons.  Other potassium sparing diuretics such as amiloride, can be 
associated to MR antagonists to achieve BP and hypokalemia control 
(Delyani, 2000). 
 
Alongside these specific medications, PA patients may need other anti-
hypertensives belonging to other classes for which no absolute 
contraindication exists.  Figure 1 summarizes the raccomandations given by 
the Endocrine Society in the last guidelines. 
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Figure 1.1: Diagnostic and therapeutic alghoritm for PA as elaborated 
from the Endocrine Society  guidelines (Funder et al. 2016). 
 
1.2. The adrenal gland: Histology and functional zonation 
The adrenal gland is composed of two well distinguished parts: the adrenal 
cortex and the medulla.  The adrenal cortex can be further divided into three 
different zones: the zona glomerulosa (ZG), the zona fasciculata (ZF), and the 
zona reticularis (ZR) (Figure 2).  The outer layer under the capsule is the ZG.  
It is the primary site for the production of mineralocorticoids (mainly 
aldosterone in humans).  The ZG cells are characterized by a low cytoplasm 
to nucleus ratio and are arranged in an arched or arcuate pattern.  The ZF 
produces glucocorticoids and is the thickest zone (about 70%) of the cortex.  
It is composed of columns of clear cells with high cytoplasm to nucleus ratio, 
separated by capillaries.  The ZR cells are polyhedral too, but arranged as 
nests. They produce sex hormones, mainly androgens.  The medulla mainly 
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consists of chromaffin cells located in clusters and in trabeculae, and produce 
cathecolamines. 
1.2.1 Synthesis of aldosterone 
Aldosterone precursor is cholesterol, as for any other steroid hormone. In 
humans it is synthesized almost exclusively in the ZG, through the action of 
three cytochrome P-450 enzymes and one hydroxysteroid dehydrogenase. 
 
The first step consists of transport of cholesterol from the outer to the inner 
mitochondrial membrane by steroidogenic acute regulatory (StAR) protein. 
Cholesterol is then converted to pregnenolone by the CYP11A1 (or 
cholesterol side chain cleavage enzyme).  The reaction continues in the 
endoplasmic reticulum where pregnenolone is converted to progesterone by 
HSD3B2 and progesterone is hydroxylated to deoxycorticosterone by 21- 
hydroxylase (also named CYP21). 
 
The final three steps happen in the mitochondria and are mediated by a single 
enzyme, the aldosterone synthase (or CYP11B2), which catalyses 11-
hydroxylation, 18-hydroxylation, and 18-oxidation of deoxycorticosterone. 
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Figure 1.2: Haematoxylin and eosin staining of the human adrenal gland 
(low amplification). Zona glomerulosa cells are compact with low 
cytoplasm to nucleus ratio; zona fasciculata cells are clear, large, and 
lipid-laden with high cytoplasm to nucleus ratio. 
 
 
Cortisol steroidogenesis, confined into the ZF, overlaps aldosterone synthesis 
pathway until the first two reactions and the conversion of cholesterol to 
pregnenolone.  CYP17 (or 17alpha-hydroxylase) is necessary for 
pregnenolone or progesterone hydroxylation.  The last three steps are 
mediated by 3βHSD (HSD3B2), 21OHase (CYP21) and 11βOHase 
(CYP11B1).  
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Figure 1.3: Adrenal cortex steroidogenesis (figure modified from 
Hattangady et al. 2012).   
 
 
 
The anatomical separation of these biochemical events in the adrenal cortex 
layers, in other words the exclusive synthesis of aldosterone in ZG and of 
cortisol in ZF, is called “functional zonation”.  
Three phenomena maintain it: a) the exclusive ZG expression of CYP11B2, b) 
the exclusive ZF and ZR expression of CYP17A1 and CYP11B1 and c) 
absence of HSD3B2 expression, necessary for aldosterone and cortisol 
synthesis, in ZR.   
Additionally, the centripetal blood flow in the adrenal cortex avoids the 
precursors of aldosterone synthesized in the ZF from coming into contact with 
CYP11B2 specifically and exclusively expressed in the ZG, thus contributing 
to the functional separation of the adrenocortical zones.  
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1.2.2 Regulation of aldosterone  
Aldosterone synthesis is strictly regulated both acutely (within minutes from 
stimulus) and chronically (hours to days).  
The renin-angiotensin system, via the final mediator angiotensin II (AngII), 
represents the main regulator of aldosterone synthesis and secretion.  
There are two AngII receptors in the human adrenal, AT1 and AT2.  The latter 
constitutes the main fetal adrenal receptor, whereas AT1 is the principal 
binding site for AngII in the adults.   
 
Acute increases of AngII trigger several pathways and activate several ion 
transporters through it: 
 1) The activation of phosphoinositide-specific phospholipase C (PLC) which 
generates diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) from 
phosphatidylinositol 4,5-bisphosphate (PIP2);  
2) Activation of phospholipase D (PLD), which generates DAG precursor 
phosphatidylcholine (PC).   
IP3 activates its endoplasmic reticulum (ER) receptor thus triggering the 
release of calcium into the cytosol. 
 
DAG inhibits TWIK-related acid sensitive (TASK or “leak”) potassium 
channels that maintain the resting membrane potential thus inducing 
depolarization. Additionally, AngII induces depolarization of ZG cell due to the 
activation of the voltage-gated L-and T-type calcium channels, which mediate 
calcium influx and contribute to increase intracellular calcium concentration, 
and activation of calcium/calmodulin-dependent protein kinases I/II (CaMK), 
as well as PKC.   
 
CaMK and PKC regulate StAR phosphorylation and expression by activating 
cAMP-response element binding protein (CREB).  DAG metabolite 12-
hydroxyeicosatetraenoic acid (12-HETE) also positively acts on the 
phosphorylation (and activation) of CREB.  
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Similar to AngII, small increases in extracellular potassium levels also 
stimulate calcium influx, via depolarization of the glomerulosa cell plasma 
membrane and activation of the voltage dependent calcium channels, 
transient T-type and long-lasting L type. 
 
ACTH can stimulate aldosterone production only acutely.  Acute stimulation 
involves the binding of ACTH to its receptor, the melanocortin type 2 receptor 
(MC2R), activation of the adenylate cyclase (AC), and increased production of 
cAMP.  This second messenger activates protein kinase A (PKA), which 
increases both expression and activation of StAR.  Activated PKA also 
increases calcium influx through L-type calcium channels.  These 
mechanisms are represented in figure 1.4 
 
Chronic regulation of aldosterone is mainly mediated by the induction of 
CYP11B2 expression in the ZG.  AngII can also up-regulate its own receptor.  
The signaling cascades involved in chronic AngII stimulation are the ones 
involved in acute. PKD signaling is involved too, but one of the best 
characterized is the PLC-mediated generation of DAG and IP3, which 
increases intracellular calcium activating CaMK.  Calcium signaling appears to 
be the primary regulator of CYP11B2 transcription. 
 
DAG-activated PKC inhibits the expression of CYP17A1. AngII stimulates 
CYP11B2 expression through the activation of its transcription. AngII 
stimulates different transcription factors such as CREB and nuclear receptor 
related 1 protein encoded by NURR1 (also known as nuclear receptor 
subfamily 4, group A, member 2, NR4A2).  It also up-regulates the expression 
of LDL and HDL receptors to provide the ZG cells of cholesterol.  Moreover, it 
induces ZG hypertrophy and hyperplasia. 
 
Chronic exposure to potassium in either animal models or in vitro models 
such as H295R induces an up-regulation of CYP11B2.  Potassium signaling 
in ZG cells finally causes activation T- and L-type calcium channels causing 
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depolarization of the cells and increased calcium influx. Calcium binds 
calmodulin (CaM) and the complex activates several enzymes and ZG 
specific kinases, many of which are expressed in a tissue-specific manner, 
such as CaM kinases (CaMK) types IV and I.  These mechanisms are 
represented in figure 1.5. 
 
 
Figure 1.4: Acute actions of AngII, K+ and ACTH on adrenal glomerulosa 
cell aldosterone production (from Hattangady et al. 2012). 
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Figure 1.5: Regulation of the chronic production of aldosterone by AngII 
and potassium (K+) (from Hattangady et al. 2012). 
 
1.2.3. Intracellular Ca2+, depolarization and cation channels: a functional 
union. 
The two most important aldosterone secretagogues (ANG II and K+) cause 
ZG cell depolarization, the principal mechanism driving to an increase of 
[Ca2+]i . 
The membrane potential of ZG cells is determined by the distribution of 
diffusible ions and their selective conductance through plasma membrane.   
 
The Na+-K+ and Ca2+ pumps are responsible for the asymmetrical distribution 
of the major cations, and are modulated by AngII.  The Na+-K+-ATPase (also 
called sodium pump) greatly contributes in maintaining the rest membrane 
potential hyperpolarized by exchanging three cytoplasmic Na+ for two 
extracellular K+.  ANG II inhibits its activity, thus dissipating the K+ gradient 
and resulting in depolarization. 
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The ZG membrane potential is close to the predicted equilibrium potential of 
K+ (-70/-90 mV), therefore other K+ conductances are also of great 
significance in setting it.  Several voltage gated K+ channels had been 
identified in ZG cells, as instance outward rectifier, Ca2+-dependent and maxi-
K+ channels, some of which slowly voltage activating/voltage inactivating or 
noninactivating, but most of them are inactive at the negative resting 
membrane voltages and, although inhibited by ANG II in experimental 
conditions, they cannot induce the required depolarization for aldosterone 
secretion.  Between the K+ channels active in ZG cells (leak and inward 
rectifiers), only leak K+ currents have been recorded at both single channel 
and macroscopic levels. Nevertheless both leak and inward rectifier K+ 
channels had been described to be involved in the physiopathology of PA, as 
described below. 
1.2.4 K2P channels and leak K currents 
The leak currents recorded in adrenal ZG share all leak K+ channels features, 
i.e the apparent rectification in physiological solutions is caused exclusively by 
unequal K+ concentrations on the two sides of the plasma membrane.  Their 
role in ZG cells is to stabilize the negative resting membrane potential and 
counterbalance depolarization. 
The most highly expressed K+ channels in the ZG are the TASK (TWIK 
[tandem of P domains in a weak inward rectifying K channel]-like, acid-
sensitive K+ channel) channels, in particular TASK1 and TASK3, which belong 
to the two pore domain K+ (K2P) channel family.  In recent years, single or 
combined knock out mouse models had highlighted their functional role. 
TASK-1-/- mice have hypertension, low plasma renin and a sexually dimorphic 
hyperaldosteronism independent of salt intake; the phenotype is correlated to 
sex and sexual hormones.  
TASK3-/- mice have only mild hyperaldosteronism resembling low-renin salt-
sensitive hypertension, with suppressed plasma renin activity, 
nonsuppressible aldosterone with salt, increased aldosterone/renin ratio, 
hypersensitivity to ANG II.  The adrenal cells from this model were also 
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profoundly depolarized.  The adrenal phenotype of the TASK-3-/- mice is 
severe in neonatal mice and becomes milder in the adult (Davies et al., 2008).   
 
The TASK-1-/-/TASK-3-/- double knockout mice exhibited no TASK-like 
currents, resulting in an approximately 20-mV baseline membrane 
depolarization and markedly increased (+400%) aldosterone production.  
Plasma aldosterone was increased by a low-sodium diet but again not 
suppressible by high salt intake.  Candesartan, an ANG II receptor blocker, 
partially suppressed aldosterone increase, revealing that regulation of its 
production in this double knockout is at least partially preserved, probably 
because other potassium channels compensate for the loss of TASK-1 and 
TASK-3. (Guagliardo et al., 2012) 
In humans, a possible influence of genetic variants (single-nucleotide 
polymorphisms (SNPs)) in KCNK9 (coding for TASK3) on BP and aldosterone 
levels had been recently described in a study on healthy subjects, while no 
associations were found with KCNK3 (coding for TASK1). (Jung et al., 2012) 
1.2.5 Mechanisms of action of aldosterone 
The main function of aldosterone as mineralocorticoid is to maintain the 
extracellular volume and blood pressure and to control potassium 
homeostasis by its effects of increasing sodium retention and potassium and 
hydrogen ions secretion in the distal nephron, the distal colon and sweat 
glands.  Aldosterone activates the MR, which is located in the cytosol of the 
target cells when inactive and moves to the nucleus when binds aldosterone.  
MR has similar binding affinity for aldosterone and cortisol, but cortisol is 
inactivated to cortisone by 11beta-hydroxysteroid dehydrogenase type 2, thus 
preventing MR activation in conditions of increased cortisol levels.  
 
Aldosterone has both genomic and non-genomic effects. Activated MR when 
localized into the nucleus can affect gene expression acting as a transcription 
factor.  
  
 
 
 
 
29 
The target gene mediating the classic mineralocorticoid effects of aldosterone 
in the distal nephron is the epithelial sodium channel (ENaC). Activated MR 
stimulates the expression of its alpha subunit, and prevents its degradation by 
increasing the expression of the sgk kinase, which inactivates by 
phosphorylation Nedd4-2, a regulator of ENaC ubiquitylation. 
 
Aldosterone also increases the expression of ROMK in the distal convoluted 
and collecting duct cells, thereby enhancing the tubular capacity to excrete 
potassium, but only if potassium is elevated and extracellular volumes are 
normal. 
 
MR is expressed in several other non-epithelial cells where its activation can 
contribute to the control of blood pressure, and consequently to HT when 
aldosterone secretion is excessive.   
 
Faster non-genomic effects of aldosterone do not affect gene expression and 
are not prevented by MR blockers such as spironolactone.  They are 
mediated by the interactions of aldosterone with MR or other receptors in the 
cell membrane, and are due to the activation of several signaling pathways, 
transporters and channels.  
1.2.6. Consequences of aldosterone excess 
Aldosterone excess, relatively to the extracellular volume homeostasis, 
causes sodium retention and volume expansion, and its eventual clinical 
manifestation is HT.  Urinary potassium is also not retained in the distal 
tubule, with consequent hypokalemia. The augmented urinary excretion of 
hydrogen ions can cause metabolic alkalosis. 
 
In addition to these effects, HT and cardiovascular complications due to 
aldosterone excess are also mediated by MR activation in tissues other than 
epithelia.  Aldosterone excess in fact causes endothelial dysfunction and 
vascular remodeling, enhance sympathetic outflow, and impair baroreflex 
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function, and in PA these may be additional mechanisms contributing to 
developing HT and cardiovascular damage.  
From a clinical standpoint, it is known from several studies that aldosterone 
excess causes inflammation, remodeling, and fibrosis in cardiovascular 
tissues, and this is independent from its BP effects and from the severity of 
HT.  This has been shown both in animal models and in clinical studies that 
have confirmed the increased cardiovascular damage in PA patients in 
comparison to essential HT subjects matched for HT degree.  Several 
markers and predictors of cardiovascular events are in fact more severe in PA 
patients, such as left ventricular hypertrophy, fibrosis, carotid intima-media 
thickness and femoral pulse wave velocity.  This increased amount of damage 
would translate in increased rates of cardiovascular events (stroke, coronary 
syndromes, arrhythmias) and mortality. 
 
Aldosterone damage on kidney, independent on HT and its action on 
extracellular volume and potassium homeostasis, is due to MR mediated 
fibrosis and vascular and tubular inflammation.  Clinically, PA patients have 
higher urinary albumin excretion, higher creatinine clearance (both due to 
glomerular hyperfiltration) and increased intrarenal vascular resistance than 
matched essential hypertensives.  The resolution of glomerular hyperfiltration 
by specific PA treatment can unmask the real kidney function impairment by 
prolonged aldosterone excess with decline of the eGFR. 
1.2.7 Metabolic effects of aldosterone excess 
In recent years, there has been compelling evidence that PA is associated to 
the “metabolic syndrome”.  Body mass index correlates positively with 
aldosterone levels in normal subjects and hypertensives, and different studies 
have reported that hyperglicemia, metabolic sindrome and insuline resistance 
are more prevalent in PA patients and their biochemical indexes improved 
after specific treatment in APAs, although the studies reported small number 
of cases.  These effects on glucose metabolism could be due to both direct 
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aldosterone effects or to hypokalemia (Fallo et al., 2006; Giacchetti et al., 
2007). 
  
1.2.8 Psychological effects of aldosterone excess 
 PA reported also to cause an impairment quality  about adverse 
psychological effects and is associated to depression, anxiety  lethargy, 
fatigue.  Moreover they may find some resolution after specific medical 
teatment or adrenalectomy (Ahmed et al., 2011). 
 
1.3. Aldosterone producing adenomas and genetic abnormalities 
Recent advances in genome sequencing techniques helped researchers to 
discover part of the genetic abnormalities involved the development and 
pathophysiology of sporadic and familial hyperaldosteronism.  
Genes encoding for ion channels (KCNJ5 and CACNA1D, ATP1A1 and 
ATP2B3) involved in intracellular ionic homeostasis and cell membrane 
potential regulation have been identified as mutated in sporadic APAs.  
Germline mutations of KCNJ5 are responsible for familial hyperaldosteronism 
type 3; germline CACNA1D mutations have been identified in two patients 
with PA and neurological symptoms.  These mutations are present in about 
50% of all tumors. 
1.3.1. Familial Hyperaldosteronism- introduction 
So far, four types of familial hyperaldosteronism have been described. Their 
prevalence is quite low:  type I accounts for <1% of PA cases, type II has 
been reported to have a prevalence of about 7% in one series of patients, 
type III and IV are extremely rare. 
1.3.2. Familial Hyperaldosteronism Type I 
The first familial form of PA described is the autosomal dominant, 
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glucocorticoid-remediable PA, also known as Familial Hyperaldosteronism 
Type I (FH-I). 
The underlying genetic abnormality is the presence of a “chimaera gene” 
mutation, made of CYP11B1 sequences at 5’ end and CYP11B2 sequences 
at its 3’ end. The encoded enzyme is able to synthesize aldosterone but is 
under the regulation of ACTH and not the RAS (Lifton et al., 1992). 
Therapeutically, aldosterone overproduction and the consequent biochemical 
pattern of PA and HT are controlled by small doses of glucocorticoids that 
down-regulate the expression of the hybrid gene. 
In the adrenal cortex of these patients, the normal zonation is abolished and 
aldosterone synthesis occurs in both ZG and ZF.  Moreover, hybrid steroids 
18 hydroxy- and 18 oxo-cortisol are highly synthesized.  
The clinical phenotype of FH-I is variable in terms of onset and severity of HT.  
The most severe cases present resistant HT and cerebrovascular 
complications such as hemorrhagic stroke.  However, the resolution of HT 
and PA is prompt and rapid with small doses of corticosteroids even in 
patients with severe manifestations. 
 FH-I should be suspected in patients with familiarity for PA, early age 
diagnosis, history of haemorrhagic stroke and suppression of aldosterone 
after a dexamethasone suppression test. Long-PCR test should be performed 
to confirm the diagnosis. 
1.3.3 Familial Hyperaldosteronism Type II 
FH-II is diagnosed when not glucocorticoid-suppressible PA occurs in families 
in an autosomal dominant way and FH-I or FH-III is definitely excluded.  Its 
clinical, biochemical and radiological presentation are very close to non-
familial, sporadic PA. 
Patients with FH-II features are not significantly different from those with 
apparently non-familial PA. Affected members from the same family can have 
different PA subtypes and phenotype in terms of AngII responsiveness and 
cellular composition of the APAs. 
The real prevalence of FH-II is unknown because ARR-based screening for 
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PA is not routinely and extensively performed in relatives of PA patients. 
The genetic abnormality underlying FH-II is still unknown.  So far, linkage 
studies only identified a locus at chromosome 7p22, but no mutation has been 
found (Carss et al. 2011). 
Other forms of FH are described in the following paragraph as they are 
closely connected with the recent discovery of somatic mutations in sporadic 
APAs. 
1.3.4 KNCJ5 mutations, sporadic APA, and Familial Hyperaldosteronism-
III 
Recent applications of next-generation sequencing (NGS) in APA research 
have enlightened novel genetic abnormalities in both sporadic and familial 
forms of PA.  
KCNJ5 encodes the G-protein activated potassium inwardly rectifying channel 
Kir3.4, which is made of 419 amino acids and is expressed in several tissues 
and cell types.  In the adrenal cortex, KCNJ5 is localized mainly in the ZG and 
the outer part of ZF (Figure 1.6).  
The channel has two membrane- spanning domains, cytoplasmic NH2 and 
COOH termini, and the channel’s ion selectivity filter is localized in an 
extracellular pore-forming loop. Its function in physiological conditions is to let 
potassium ions cross the pore and enter the cytoplasm while preventing the 
entrance of sodium ions. 
Choi et al. discovered, by using whole exome sequencing, germline and 
somatic mutations in KCNJ5 in samples from patients with either the familial 
or sporadic form of APA (Choi et al. 2011). 
Two hot spot somatic mutations were at G151R and L168R, situated on the 
conserved glycine–tyrosine–glycine (GYG) motif of the selective filter and the 
second transmembrane (TM) domain of KCNJ5, respectively.  G151R and 
L168R, associated with sporadic APAs, and in following confirmation studies 
resulted to be the most common mutations in KCNJ5 mutant sporadic APAs. 
The mutations cause the loss of the K+ selectivity of the channel, which leads 
to higher Na+ conductance and depolarization of the cell, followed by the 
  
 
 
 
 
34 
opening of the voltage-gated Ca2+ channels, increased influx of Ca2+ and 
increased aldosterone production.  
The first family affected by FH-III was described as a severe form of PA, with 
important hypokalemia, resistant HT, and enlarged adrenals on both sites 
(Geller et al. 2008). In this family, a germline mutation (T158A) was identified 
in the KCNJ5 gene as responsible for the syndrome (Choi et al. 2011) .  
Following the first description, six more families and three germline KCNJ5 
mutations (G151R, G151E, p157S) were described (Mulatero et al. 2012; 
Scholl et al. 2012; Charmandari et al. 2012). In vitro all the mutations causes 
the same changes described before. 
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Figure 1.6: From the top left quadrant in a clockwise sense: 
Haematoxylin & Eosin staining of normal adrenal cortex; IHC of KCNJ5 
encoded potassium channel Kir3.4.; IHC of CYP11B1 encoding for 
cortisol synthase; iv) IHC of CYP11B2 encoding aldosterone synthase  
Of note, Kir3.4 is localized mainly in the ZG and the outer part of ZF. 
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Figure 1.7: Role of KCNJ5 and its mutation in the regulation of 
aldosterone synthesis.  (A) Adrenal glomerulosa cells have a high 
resting K+ conductance and hyperpolarized membrane potential (B) 
Membrane depolarization activates voltage-gated Ca2+ channels, 
increasing intracellular Ca2+ and stimulation of aldosterone synthase 
expression and cell proliferation. (C) KCNJ5 mutant channels conduct 
Na+, resulting in Na+ entry, chronic depolarization, constitutive 
aldosterone production, and cell proliferation. (Modified from Choi et al. 
2011). 
 
 
1.3.5 CACNA1D mutations 
The 2013 exome sequencing studies on sporadic and familial APAs led to 
discovery of new mutations in CACNA1D (Azizan et al. 2013; Scholl et al. 
2013).  In particular, our group studied 10 APAs with ZG-like phenotype, 
KCNJ5 wild-type and reported that 9 over 10 have mutations in either 
ATP1A1 or in CACNA1D. 
CACNA1D encodes the pore-forming a1D subunit of a voltage-gated L-type 
calcium channel (Cav1.3) which is composed of further b, a2d, and g auxiliary 
subunits.  a1D’s four homologous repeats (I–IV) have six transmembrane 
segments (S1–S6).  
Unlike KCNJ5, ATP1A1, and ATP2B3, the 21 somatic CACNA1D mutations 
reported so far are not localized in hotspot(s) but occur throughout the gene, 
around transmembrane segments S4, S5, and S6, which play a role as with 
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the channel’s activation gate and voltage sensing, and the cytoplasmic S4–S5 
linker coupling the voltage-sensing domain to the pore.  
Patch clamping showed that the gain-of-function CACNA1D mutations 
increase intracellular calcium concentration through few different effects on 
the channel activity and status: shifting voltage dependent activation of the 
channel to more negative potentials, slowing inactivation, and/or increasing 
currents through a higher open channel probability. 
Scholl et al. also reported two cases of early-onset HT and PA with germline 
mutations in CACNA1D.  The first case had HT at birth, with PA and 
hypokalemia, biventricular hypertrophy, a ventricular septal defect, pulmonary 
hypertension, and second-degree heart block. Treatment with a calcium 
channel blocks normalized blood pressure and biventricular hypertrophy. 
Neurological symptoms included seizures, apparent cerebral palsy, cortical 
blindness, and complex neuromuscular abnormalities. The second case was 
born with cerebral palsy, spastic quadriplegia, severe intellectual disability, 
and seizures. At age 5 years, she had HT, polydipsia, hypokalemia and 
metabolic alkalosis and PA with no adrenal masses (Scholl et al., 2013). 
1.3.6 ATP1A1 and ATP2B3 mutations 
After the initial identification of KCNJ5 mutations in 2011, two further NGS 
studies were performed in KCNJ5 wild-type APAs (Azizan et al. 2013; 
Beuschlein et al. 2013) and led to the discovery of gain-of-function mutations 
in two P-type ATPase pumps, ATP1A1 and ATP2B3.  ATP1A1 corresponds to 
the catalytic alpha1 subunit of the Na/K-ATPase. The pump exchanges three 
cytoplasmic Na+ ions for two extracellular K ions against their concentration 
gradient, regulating the resting cell membrane potential.  
ATP2B3 encodes the plasma membrane Ca2+-ATPase isoform 3, a regulator 
of intracellular calcium homeostasis that pumps calcium ions out of the cell 
against gradient.  
 
The L104 residue in transmembrane helix M1 and the V332 in M4 are in close 
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approximation to residue E334 crucial for K+ binding and gating. The mutant 
L104R has impaired ion binding, and no Na+/K+- ATPase pump activity. The 
Na+-dependent phosphorylation is also reduced.  Electrophysiologically, cells 
carrying ATP1A1 mutations are more depolarized.  Removal of extracellular 
Na+ exaggerated the expected hyperpolarization, supporting the hypothesis 
that the mutations did not involve higher Na+ conductance causing 
depolarization, but caused disturbed intracellular ion composition.  
Beleuschlein et al. concluded from these results that aldosterone 
overproduction is due to the loss of functional ATP1A1 pump activity as a 
consequence of the haploinsufficiency. 
Our group discovered at the same time the same ATP1A1 mutations in ZG-
like APAs, and we have suggested that gain-of-function occurs.  
The wild type pump generates a current at positive membrane potentials 
stimulated by extracellular K+. L104R and del100_104 and V332G mutants 
pumping activity was not sensitive to K+, however at physiological membrane 
potentials they were marked ouabain-sensitive, producing a voltage-
dependent inward current partially inhibited by K+.  
 Moreover, while removal of extracellular Na+ had little effect on the reversal 
potential, a change in pH of 1 changed the reversal potential by about 20 mV, 
suggesting that protons were the main carrier of the current in the L104R 
mutant enzyme. 
Reversely Na+ was the main carrier of current in del100_104 mutant as 
its removal shifted the reversal potential while changes in pH did not.  
Rearrangements of the M1 helix caused a broader opening responsible of Na 
leak.  
Transfection of the H295R with the rat ouabain-insensitive wild type and rat 
mutant L104R cDNA showed an increased in aldosterone secretion and 
expression of the CYP11B2 mRNA when incubated with ouabain or 
angiotensin II. 
The ATP2B3 mutations stimulate aldosterone production by losing the 
physiological pump function and reducing Ca2+outward currents, alongside 
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opening of depolarization-activated Ca2+channels and Ca2+ leak through the 
mutated pump thus increasing calcium influx.  
 
 
Figure 1.8: Proposed model of changes in the electrical properties of 
APA cells carrying mutations in the ion channels discovered so far 
(from Zennaro et al. 2015). 
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1.3.7 CTNNB1 mutations 
CTNNB1 mutations were reported in two exome sequencing studies, then 
reported in a Swedish cohort(A. E. D. Teo et al. 2015; Åkerström et al. 2016).  
Of interest, CTNNB1 mutated APAs occurred almost exclusively in female 
patients.  In three female patients the diagnosis was unmasked by pregnancy 
or menopause (A. E. Teo et al. 2015). 
The reported mutations (S33C, G34R, A39Efs_3, T41A, S45P, and S45F) 
involve serine/threonine residues in exon 3 that, if phosphorylated, address 
beta-catenin to degradation. When a mutation occurs, beta-catenin is not 
phosphorylated nor degraded, thus causing constitutive activation of the Wnt 
signaling and high CYP11B2 expression. 
These mutations also cause adrenocortical cells de-differentiation toward the 
adrenal-gonadal precursor cell type, with high expression of gonadal 
receptors LHCGR and GNRHR, which would explain the clinical phenotype of 
the three cases. 
Both the adrenal cortex and the ovaries originate from a common progenitor-
cell population, and gene expression regulating the differentiation and cell fate 
is SF1-dependent and regulated by the Wnt signaling pathway.  Transfection 
of primary ZG-like adenoma cells with mutant CTNNB1 led to expression of 
LHCGR and GATA4, markers of gonadal differentiation normally unexpressed 
in adrenal cells. 
Previous studies showed that GNRH activation of transfected GNRHR 
stimulates CYP11B2 expression and aldosterone synthesis in H295R. 
Therefore, aldosterone synthesis is likely to increase during pregnancy when 
these aberrant gonadal receptors are stimulated.  
1.3.8 Prevalence of Somatic Mutations and Genotype/Phenotype 
Correlations 
As mentioned previously, KCNJ5 mutations are the most common genetic 
abnormalities in sporadic APAs.  Since the first study, there have been 
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several prevalence studies from different research groups worldwide 
(Boulkroun et al. 2012; Taguchi et al. 2012; Åkerström et al. 2012; Williams et 
al. 2014; Azizan et al. 2012).  The prevalence of KCNJ5 mutations varies 
between 30–65% in different cohorts, with a higher prevalence in the Asian 
population and among females (~70%).  G151R and L168R are the most 
frequent, but overall 15 different mutations have been reported, also near or 
within the selectivity filter.  
 
After KCNJ5, mutations in the CACNA1D are the second most frequent in 
sporadic APAs, reported to be up to 11% (Scholl et al. 2013).  ATP1A1 and 
ATP2B3 are rarer, below 10% (Fernandes-Rosa et al. 2014).  
beta catenin mutations have a similar mutation rate, between 2 and 5% 
(Akerstrom et al., 2016; Wu et al., 2017). 
Fascinatingly, the clinical and biochemical parameters of patients with a 
somatic CACNA1D mutant APA differed from those with a somatic KCNJ5 
mutant APA. 
Although patients with wild-type and KCNJ5 mutant APAs did not show any 
difference in terms of clinical BP and serum potassium levels, patients with 
KCNJ5 mutant APAs have higher aldosterone levels. 
Moreover, they are more frequently female, had larger adenomas, and were 
treated by adrenalectomy at a younger age. One studied reported that they 
also have higher lateralization ratios  at AVS thus explaining the earlier 
diagnosis and treatment, alongside the fact that these adenomas have bigger 
dimensions and are also easy to be detected at the conventional imaging 
(Seccia et al., 2012). 
One study by Williams et al. found that specific somatic mutations in APAs 
present with distinct steroid profiles in the lateralization side and in peripheral 
blood plasma.  
APA carrying a KCNJ5 mutation have in fact higher concentrations of hybrid 
steroids 18-hydroxycortisol, and 18-oxocortisol, which can be explained by the 
phenotypical differences found in comparison to KCNJ5 wild-type APAs 
(Williams et al. 2016). 
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Histologically, these tumors are mainly composed of large, lipid-rich, zona 
fasciculata-like cells whereas APAs carrying CACNA1D mutations have 
histological resemblance to small and compact ZG-like cells. 
Transcriptome analysis found that CYP17A1A1 and CYP11B1, encoding the 
steroidogenic enzymes involved in cortisol synthesis, were highly expressed 
in ZF-like, KCNJ5 mutant APAs when compared to the ZG-like, KCNJ5 wild-
type APAs (Azizan et al. 2012).  Thus, 11-deoxycortisol is highly synthesized 
and becomes substrate for CYP11B2 converting it to 18-hydroxycortisol and 
18-oxocortisol. 
1.3.9 APCCs and new hypothesis about the cellular origin of APA 
The progression from normal adrenal to APA is still not well understood. 
Of interest, aldosterone synthesis is suppressed and zona glomerulosa does 
not express CYP11B2 encoding aldosterone synthase thoroughly but this 
enzyme shows a patchy expression pattern at IHC.  CYP11B2 positive cells 
clusters (APCCs) are the only areas in adrenal cortex expressing aldosterone 
synthase and are located below the adrenal capsule, extending into ZF.  
Mixed cell composition in APCCs includes both ZG like and ZF like cells that 
often show a zonation pattern recalling the normal zonation of adrenal cortex, 
although ZF-like cells in APCCs express CYP11B2. 
 
This phenomenon is likely to be connected to high salt intake with the western 
diet, which abolishes the need of high aldosterone production to save salt and 
water.  Moreover, APCCs are also present in normal adrenal glomerulosa 
adjacent to APA despite the low renin levels, thus suggesting that aldosterone 
synthesis in these cells differ from other ZG cells in terms of independence 
from the RAS. 
 
Nishimoto et al. have found that, in normal adrenals from donors, APCCs are 
a common finding and have performed sequencing and microarray analysis 
and found that APCCs cells have APA-related somatic mutations. These 
mutations are localized in known ion channels/pumps (ATP1A1 and 
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CACNA1D (Nishimoto et al. 2015). These findings may suggest that APCCs 
are pre-adenomatous lesions leading to ZG-like APAs. 
Of interest KCNJ5 mutations have not been found in APCCs although 
mutations in this gene are the commonest in sporadic APAs.  If KCNJ5 
mutations arise in ZG cells and stimulate CYP11B2 expression, KCNJ5 
mutant APCCs are not detected probably because of a rapid evolution in 
APAs or because a second hit mutation is necessary. 
 
1.3.10 Study Hypothesis 
Cells composing APAs present different histological phenotypes: there are 
ZF-like cells (cells morphologically similar to normal ZF cells with a high 
cytoplasm to nucleus ratio and cytoplasm occupied by lipid vacuoles), ZG-like 
cells (compact cells similar to normal ZG cells with a low cytoplasm to nucleus 
ratio and no or little lipid droplets), and intermediated cells with a ‘hybrid’ 
characteristics of both.  
APAs could be classified according to the percentage of ZG-like and ZF-like 
cells in two subtypes, ZG-like and ZF-like APAs that differ not only 
histologically but biochemically and genotypically. The latter usually have 
KCNJ5 mutations; the small ZG-like APAs are KCNJ5 wild type. 
 
The finding of common gain-of-function mutations in a distinct group of ZG-
like APAs led to the question whether these tumours arise from normal 
adrenal ZG cells, and if ZG- and ZF-like APAs differ in terms of tumorigenesis.  
 
We have undertaken a microarray analysis comparing normal adrenocortical 
ZG with ZF using LCM (figure 1.9) to define ZG-specific genes. We have then 
compared the transcriptome of 5 ZG-like APAs with mutations in CACNA1D 
or ATP1A1, to 8 ZF-like APAs with mutations in KCNJ5.  The clinical data of 
the APA patients are showed in Table 1.1.  
 
The finding of previously unsuspected genes with markedly up-regulated 
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expression in adrenal zona glomerulosa could provide insight to pathways 
involved in the regulation of aldosterone production. The top 20 of 213 of ZG-
up-regulated genes are showed in Table 1.2. 
 
The main genes studied are ANO4 and NEFM. We have hypothesized that 
they may be involved in the regulation of aldosterone in normal ZG and, in 
case of NEFM, in ZG-like APAs.  The primary aim is to determine the effects 
of over-expression and/or partial knockdown of each of these genes in human 
adrenal cells. 
 
 
 
Table 1.1: The clinical features of the patients with Conn’s syndrome 
involved in the microarray assay. We did not have any clinical data 
about the Phaeocromocytoma patients. ZG: zona glomerulosa. APA: 
Aldosterone producing adenoma. AAG: adjacent adrenal gland. 
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Figure 1.9: Histological images showing laser capture microdissection 
of ZG and ZF from adrenal sections. 
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Gen
e # 
 
Gene 
Symbol 
Fold-
Change 
(ZG vs ZF) 
P-value 
(ZG vs ZF) 
Transcript ID  
RefSeq 
1 
LGR5 
25.05 1.57E-23 7957140 NM_003667 
2 VSNL1 23.57 3.65E-23 8040430 NM_003385 
3 ANO4 19.89 6.58E-24 7957861 NM_178826 
4 NEFM 14.80 9.16E-12 8145361 NM_005382 
5 VCAN 14.34 1.85E-13 8106743 NM_004385 
6 DACH1 14.24 1.38E-21 7971950 NM_080759 
7 
NR4A2 
10.90 6.16E-08 8055952 NM_006186 
8 KIAA1210 8.90 5.40E-11 8174670 NM_020721 
9 SFRP4 8.67 2.30E-10 8139087 NM_003014 
10 C12orf75 7.22 4.37E-13 7958253 NM_001145199 
11 C9orf84 6.95 5.10E-13 8163348 NM_173521 
12 VAT1L 6.88 9.16E-17 7997336 NM_020927 
13 EDNRA 6.50 1.18E-16 8097692 NM_001957 
14 OGN 6.34 5.15E-12 8162373 NM_033014 
15 NR4A3 5.92 3.06E-08 8156848 NM_006981 
16 SESN3 5.89 6.10E-16 7951077 NM_144665 
17 LEF1 5.88 4.29E-15 8102232 NM_016269 
18 PLD5 5.86 2.55E-12 7925511 NM_152666 
19 CDH12 5.81 4.45E-10 8111234 NM_004061 
20 HLF 5.75 5.69E-16 8008588 NM_002126 
 
Table 1.2: Top 20 of the 213 up-regulated genes in all zona glomerulosa 
(ZG) vs all zona fasciculata (ZF) (FC>5, P < 0.05) (Zhou et al., 2015). 
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Chapter 2: Study design and general methods  
2.1 Study design 
Small ZG-like APAs are undiagnosed because of their small size, although 
new imaging techniques such PET-CT scan can facilitate their detection. 
 
 In the following study, we have sought signature ‘ZG-genes’ which may 
provide insight to the frequency and pathology of ZG-like APAs. ANO4 and 
NEFM, two top up-regulated ZG genes in our microarray result were subjects 
for further analyses due to their high selectivity in expression and probable 
role in aldosterone production regulation.  
The role these genes on steroidogenesis was assessed in the human 
adrenocortical cell line, H295R, and in primary adrenal cells. This was done 
through silencing using short interfering RNAs and through overexpressing 
using a plasmid expression vector.  
Further, due to association in literature of NEFM with the dopamine D1 
receptor, we performed pharmacological and IF experiments investigating the 
effects of silencing NEFM on this receptor. 
ANO4 effect on basal and stimulated aldosterone secretion was compared to 
those of other anoctamins, ANO1 and ANO6. ANO4-mediated chloride 
currents were measured using YFP assay. 
Further details on study design and specific methods are present in each 
chapter. 
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2.2 General Methods 
 2.2.1 Human adrenal tissue  
Human adrenal tissues were obtained from patients with an APA or a 
Phaeocromocytoma who underwent adrenalectomy at Addenbrookes 
Hospital, Cambridge.  Local ethical approval and informed consent were 
obtained from each patient.  
 
Within half hour of the surgery, fresh adrenal tissues from adrenalectomy 
were separated from surrounded fat tissue.  Subsequently, the tissues were 
processed differently for different purposes of future use:  
 
(a) For RNA extraction: Tissue blocks of about 0.5×0.5×0.5 cm3 from tumor or 
normal tissue were dissected by an adrenal histopathologist and stored in 
RNAlater (Ambion, USA) in separate vials immediately.  After keeping at 4°C 
overnight to allow the RNAlater enter the tissues, the solution was removed 
and the vials were stored at -70°C for long-term storage.  
 
(b) For protein extraction: Same normal and tumor tissue blocks as prepared 
for RNA extraction were prepared for protein extraction.  The sample was put 
into a vial sitting on ice with RIPA lysis buffer (Thermo Fischer) and complete 
protease inhibitor cocktail (Roche).  Immediate homogenization was 
performed for the tissues. A maximum of twice homogenization was applied to 
tissues that were not well homogenized at the first time. Then the protein 
samples were stored at –70°C for future use.   
 
(c) For cell culture: Pieces of normal and tumor adrenal glands were 
immersed in culture medium consisting of supplemented Dulbecco's Modified 
Eagle's Medium/Nutrient F-12 Ham immediately (supplemented with 100 U 
penicillin, 0.1 mg/ml streptomycin, 0.4 mM L-glutamine, insulin-transferrin-
sodium selenite media, and 10 % fetal calf serum) and then proceeded to 
digestion by collagenase (3.3 mg/mL) for primary cell culture.   
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As we did not collect normal adrenal glands for ethic issues, we used only 
adjacent adrenal gland (AAG) cortex and classified this non-tumorous tissue 
as normal. 
 
2.2.2 Primary cell culture from adrenal tissue 
Freshly collected human adrenal tissue was moved to a culture dish with 
PBS.  The medulla was carefully removed by a sterile surgery knife and the 
tissues minced in small pieces which were left into in 3.3 mg/ml collagenase 
(Sigma, USA) in warm media, at 37 °C for at least 2 hours to allow digestion.  
After that, the suspension was centrifuged to pellet the cells and discard the 
media with the enzyme.  The cells were then washed by PBS twice and re-
suspended in culture medium. The primary cells were cultured in 37 °C 
incubator in 5 % CO2 for at least 4-7 days, then plated for experiments. 
2.2.3 Human adrenocortical cell line  
H295R (NCI-H295R) cells are the only human adrenal cell line capable of 
proliferate and secrete aldosterone. This is a subgroup of NCI-H295 cells 
derived from a human adrenal carcinoma excised from a 48-year-old black 
female (Gazdar et al. 1990).  All the major adrenocortical steroids are 
produced by NCI-H295 cells, including aldosterone, cortisol, corticosterone, 
androgens and respond to AngII and potassium.  H295R cells are a strain of 
cells from NCI-H295 which grow faster and in a monolayer. They carry a 
mutation in CTNNB1 gene (Tissier et al., 2005). 
H295R cells (ATCC ® CRL-2128) were purchased from the American Type 
Culture Collection, and kept in liquid nitrogen until use.  For resuscitation, a 
vial of cells was thawed rapidly in water bath at 37°C and transferred into pre-
warmed culture medium. Only cells within passage of 10-19 were used. 
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2.2.4 Human brain and kidney tissue  
Human kidney and brain tissues were used in this study as the positive 
control for IHC or Western Blotting. They were obtained from Human 
Research Tissue Bank of Addenbrookes hospital upon request. Ethical 
approval was granted for this project. The Tissue Bank does not provide 
clinical nor demographic data for these controls. 
2.2.5 Human Embryonic Kidney 293 (HEK293) cell line  
HEK293 is a cell line derived from human embryonic kidney cells grown in 
tissue culture. The source of the cells was a healthy, aborted fetus.  Alex Van 
der Eb cultured the line in the early 1970s at his lab at the University of 
Leiden; Holland Frank Graham performed the transformation with adenovirus 
5 DNA with the calcium phosphate technique invented by himself.  The 
transformation resulted in the incorporation of approximately 4.5 kilobases 
from the viral genome (Graham et al. 1977). 
The type of kidney cell that originated the HEK293 cell line is unknown, since 
embryonic kidneys contain almost all the types of cells present in the body.  
The cells may be neuronal in origin because of the presence of mRNA and 
gene products typically found in neurons, such as all the Neurofilament 
subunits (Shaw, Morse, Ararat, & Graham, 2002). 
HEK293 cell line is very popular in research since they are easy to be 
cultured, to be transfected, have a good protein production after transfection 
and are capable of inducing tumours after the injection to animals.  
2.2.6 Laser Capture Microdissection (LCM) 
LCM was used to acquire samples of ZF, ZG and APA. For differentiation of 
ZG from ZF, sections were stained with cresyl violet using the LCM Staining 
Kit (AM1935, Ambion, USA). 
Sections of fresh frozen AAG (14 µm) were thaw mounted on to polysine-
coated slides and stored at -70°C. When required, sections were fixed in 95% 
ethanol, rehydrated in 75% and 50% ethanol, stained with 1% cresyl violet, 
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dehydrated in a graded ethanol series, and immersed in Histo-Clear (AGTC 
Bioproducts, Wilmington, Massachusetts, USA),. The ZG and ZF were 
microdissected using a PALM Microlaser System (P.A.L.M. 25 Microlaser 
Technologies).  Total RNA was isolated and reverse transcribed into cDNA as 
described below with an additional step of purification using Wizard® SV 4 1 
Gel and PCR Clean-Up System (Promega, Southhampton, UK).. 
 
2.2.7 Microarray Assay 
Microarray assay was performed using the Affymetrix Human Genome U133 
Plus 2.0 Array by GenomicsCorelab, Cambridge. Fifty-six RNA samples 
acquired through laser capture microdissection were assayed—14 trios of ZF, 
ZG, and APA from patients with Conn’s syndrome and a further 7 pairs of ZF 
and ZG adjacent to a phaeochromocytoma. Seven of the APAs contained a 
somatic mutation in KCNJ5, whereas the remaining 7 were wild-type. 
Microarray results were validated by quantitative real-time polymerase chain 
reaction.  
2.2.8 Total RNA extraction  
Human adrenal tissues were stored at -70°C till RNA extraction. 1 ml of Trizol 
(Life Technologies, USA) was added to every 50-100 mg of tissues.  
For primary adrenal cells or H295R cells cultured in 24-well plates, the culture 
medium was removed and 400µl Trizol added per well.  
Total RNA was isolated on silica columns using the TRIzol® Plus RNA 
Purification System (Life Technologies, USA). DNA-free RNA was prepared 
using PureLink® DNase Set (Life Technologies, USA) according to the 
manufacturer’s instructions.  
2.2.9 Reverse transcription  
The concentration of RNA samples was quantified at NanoDrop.  cDNA was 
synthesized using the Reverse Transcription System (Promega, USA). In 
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brief, 8.9 µl of RNA sample, 1 µl of random primers and 1 µl of Oligo-dT 
primers were mixed and then incubated at 70ºC for 10 min.  After cooling 
down on ice, 9.1 µl of master mix (4µl of 25 mM MgCl2, 2 µl of 10X reverse 
transcription buffer, 2 µl of 10 nM dNTP mixture, 0.5 µl of RNase inhibitor, and 
0.6 µl of AMV reverse transcriptase) was added per sample. The 20 µl 
systems were incubated at 22ºC for 15 min, 42ºC for 1 h, and 95ºC for 5 min. 
The cDNA samples were then stored at 4°C for short-term or –20°C for long-
term. Negative control consisted of RNase free water instead of sample RNA 
template plus the master mix.  
2.2.10 Quantitative Polymerase Chain Reaction (Real Time PCR, qPCR)  
Targeted mRNA expression level was measured by amplifying and 
simultaneously detecting its relative cDNA quantity at ABI 7500 system (Life 
Technologies, USA).  
In brief, 3.75 µl cDNA from previously described RT and 11.25 µl mix of  (7.5 
µl of Taqman Fast PCR Master Mix, 0.75 µl of 10X standard TaqMan ABI 
primer & probe of targeted gene, 3 µl of RNase free water) were added to 
each well of a 96-well plate in duplicate. After a short spin, the plates were 
incubated at 50 °C for 2 min to optimal Uracil N-glycosylase (UNG) enzyme 
activity, 95 °C for 10 min to activate AmpliTaq Gold enzyme, and then 45 
cycles of PCR (95 °C for 15 sec to denature, 60 °C for 1 min to anneal and 
extend). Standard TaqMan ABI primer & probes were applied for all the 
targeted genes except for custom made CYP11B1 and CYP11B2. The 
primers and probes used for these two genes are from previous literature, 
(Fallo et al., 2002) and produced by Eurofins Genomics, Ebersberg, 
Germany.18S rRNA was used as the housekeeping gene. The results were 
analyzed using the 2-ΔΔCT method.  We have included two negative controls, 
one was RNase free water and the other one was the water control of reverse 
transcription. 
2.2.11 Immunohistochemistry (IHC)  
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IHC on paraffin-embedded sections was performed at the Tissue Bank IHC 
service, Addenbrookes Hospital:  
 
It was performed on formalin-fixed, paraffin-embedded sections (4 µm) using 
an automated immunostainer with cover tile technology (Bond-III system, 
Leica Biosystems).  The commercial antibodies were used as the primary 
antibodies. The Antigen retrieval was carried out using the combination of 
heat and Bond Epitope Retrieval Solution 1 (Leica, AR9961) for 20 minutes.  
The optimal working dilution for NEFM was 1/500 and for DRD1 was 1/50. 
The Bond™ Polymer Refine Detection kit (Leica, DS9800) was used for 
detecting and visualising the antigens. Negative controls, in which primary 
antibodies were omitted, resulted in a complete absence of staining.  
 
 
When performed in our lab the following was the protocol used: 
Serial paraffin-embedded human adrenal or kidney sections (4 µm thickness) 
were prepared by Human Research Tissue Bank of Addenbrookes hospital 
upon request.  The slides were de-paraffinized in 2 changes of histo-clear II, 
10 min each and then transferred to 100% methanol for 2 changes, 5 min 
each. After this, the slides were transferred once through 90%, and 70% and 
methanol, 5 min each.  The slides were rinsed by Milli-Q (MQ) purified water. 
To unmask the antigenic epitope, the slides were incubate at 100°C for 15 
min in univer Vector® antigen unmasking solution (15 ml in 1600 ml MQ 
water, Vector laboratories Inc, USA) and left at room temperature for 20 min 
to cool down.  Then the slides were incubated in 0.3% H2O2 solution in 
methanol at room temperature for 4 min to block the endogenous peroxidase 
activity.  300 µl of 5% goat serum were added to the sections on the slides to 
incubate in a humidified chamber at room temperature for 2 h for blocking.  
The blocking buffer was drained off and 300 µl of diluted primary antibody in 
3% goat serum (made in PBS-T (0.1% (v/v) Tween 20 in 1x PBS)) were 
mounted on the sections to incubate in a humidified chamber at 4°C 
overnight.  The following day, the slides were rinsed in PBS-T for 3 changes, 
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5 min each.  Then, 300 µl of diluted secondary antibody in 3% goat serum 
(made in PBS-T) were mounted on the sections to incubate in a humidified 
chamber at room temperature for 1 h. The slides were rinsed in PBS-T for 3 
changes, 5 min each. 300 µl of rabbit- Peroxidase Anti-Peroxidase (PAP)-
conjugates (in 3% goat serum made in PBS-T) were added to the sections on 
the slides and incubated in a humid chamber at room temperature for 1 h. The 
slides were rinsed in PBS-T for 3 changes, 5 min each.  100 µl of DAB 
substrate solution (Sigma) were applied to the sections on the slides to reveal 
the color of antibody staining.  The slides were allowed to develop color for 
about 2 min and then rinsed by MQ water. The slides were dehydrated in 4 
changes of ethanol (95%, 95%, 100% and 100%), 5min each and then 
cleared in 3 changes of xylene and kept in xylene overnight. Finally, Depex 
was applied to the sections and the slides were covered by coverslips for 
permanent stock.  
Positive controls were prepared by applying the same antibodies to the tissue 
biologically containing abundant amount of the respective antibody, such as 
human kidney tissue, which were obtained from the Human Research Tissue 
Bank of Addenbrookes hospital.  We were not allowed to have any 
demographic or clinical data regarding these samples for ethical issues.  
Tissue incubated with the antibody diluent alone and no primary antibody, 
followed by incubation with secondary antibodies and detection reagent was 
considered as negative control. This ensures that staining is produced from 
detection of the antigen by the primary antibody and not by the detection 
system or the specimen. 
Images were captured using a standard bright field microscope, U-TV1-X 
digital camera and the CellD software (Olympus Ltd, UK).  Some slides had 
been scanned by the Tissue Bank slide scanning service using an Aperio 
Digital Pathology Scanner. 
 
2.2.12 Protein lysis and BCA™ protein assay  
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The protein samples lysed in RIPA buffer were briefly centrifuged to settle the 
debris. The supernatants were then collected as total protein of the samples. 
The components of RIPA buffer were as follows: 25mM Tris-HCl pH 7.6, 
150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS. 
The concentration of the lysate was detected by BCA™ protein assay (Pierce 
Biotechnology, USA). In brief, 10 µl of the lysate or standard curve sample 
and 80 µl of the BCA Working Reagent (50 parts of BCA Reagent A with 1 
part of BCA Reagent B) were added to each well in a 96-well plate. The plate 
was then incubated at 37°C for 30 min. The plate was then measured the 
absorbance at 562 nm on a plate reader.  
 
2.2.13 Western Blotting  
Western blotting was conducted using total protein lysate. Protein lysates 
were boiled in sample buffer at 95°C for 5 min and then separated by 
electrophoresis in 8-20% SDS-PAGE gel. The electrophoresis was run at 110 
V for 60 min until the protein ladder was well separated. The protein was then 
transferred from the gel to a PVDF membrane previously activated by 
methanol.  After that, the membrane was blocked with blocking buffer (TBS-T 
with 5%onfat dry milk) for 30 min at room temperature and then incubated in 
appropriate dilutions of primary antibody in blocking buffer at 4°C overnight. 
The membrane was washed with TBS-T three times and then incubated in 
appropriate dilution of conjugated secondary antibody in blocking buffer at 
room temperature for 1 h. The membrane was washed with TBS-T again 
three times and the bands were detected using the Pierce ECL Western 
Blotting Substrate (Thermo Fisher Scientific, USA). Anti-GAPDH (#G8795, 
Sigma, UK; 1:10,000 dilution) was used as an internal control for protein 
abundance. 
2.2.14 Aldosterone measurement 
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Commercially available Homogenous Time Resolved Fluorescence 
Resonance Energy Transfer (HTR-FRET or HTRF) assay from Cisbio 
Bioassays, France was used according to manufacturer’s instructions.  The 
aldosterone concentrations from H295R and primary cells were normalized to 
total cell protein. 
HTRF is a competitive assay using a specific antibody labeled with Eu3+-
Cryptate (donor) and aldosterone labeled with XL665 (acceptor).  
When these dyes are in close proximity, the excitation of the donor with a light 
source (laser or flash lamp) triggers a Fluorescence Resonance Energy 
Transfer (FRET) towards the acceptor, which in turn fluoresces at a specific 
wavelength (665nm).  The aldosterone present in the sample competes with 
the binding between the two conjugates and thereby prevents FRET from 
occurring.  The specific signal, inversely proportional to aldosterone 
concentration, modulates negatively. 
Briefly, the assay is performed as described: 10 ul of sample and standard 
curve points was plated in a 384 well plate in duplicate, followed by 5 ul of 
aldosterone-XL665 (100-fold stock solution previously diluted in detection 
buffer) and 5 ul of aldosterone-Cryptate antibody (100-fold stock solution 
previously diluted in detection buffer).  The plate was sealed and incubated in 
the dark for at least one hour.  The plate was then read in a compatible HTRF 
reader.  
2.2.15 Confocal Imaging 
H295R and primary cells were cultured in supplemented media on sterilised 
and poly L-lysine coated coverslips for 24-h.  
Cell plasma membranes were stained with Wheat Germ Agglutinin, Alexa 
Fluor® 633 Conjugate (W21404, Life Technologies) diluted in growth media 
(2 ug/mL) for 10 min at 37 °C.  Cells were then washed twice with PBS (5 min 
each), fixed with 4% paraformaldehyde for 10 minutes and permeabilised with 
1% triton-X100 in PBS, 5 min at room temperature.  Cells were incubated with 
blocking buffer (3% BSA in PBS-T) for 1 hr at room temperature and overnight 
with the primary antibody at optimized dilution in 3% BSA-PBS-T. Goat anti-
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Rabbit IgG, or goat anti-Mouse Alexa Fluor® Conjugates (Life Technologies) 
were used as secondary antibody at 1:500 dilution in 3%BSA-PBST for 1-h at 
room temperature.  Finally cells were washed three times in PBS and cover 
slips were mounted on slides using VECTASHIELD Antifade Mounting 
Medium with DAPI (H-1200, Vector Laboratories).  Confocal images were 
taken (63X) using Zeiss LSM510 Meta confocal microscope and analysed 
using Zen 2011 software. 
2.2.16 siRNA 
H295R cells were seeded at 1.0×105/well in 24-well plates in antibiotic-free 
complete culture medium the day before.  
The next day, the medium was removed and 500 µl of antibiotic-free medium 
with pool or individual ON-TARGETplus siRNA and non-targeting siRNA as 
control (Dharmacon) was added to the cells.  The cells were then incubated at 
37°C in 5% CO2 for 48 h and the medium harvested to measure aldosterone 
and/or protein assay or mRNA expression studies.  
For overexpression experiments H295R were seeded at the same density as 
for silencing.  The growth media was then replaced with un-supplemented 
media to starve the cells and increase the transfection efficiency.  After at 
least six hours the media was replaced by 500 ul transfection media 
containing 50 ul Optimem, 1.5 ul Lipofectamine reagent 3000, 2 ul 
Lipofectamine P3000 reagent and 500 ng of plasmid per well.  The cells were 
harvested after 48 hours for RNA or protein experiments.  
2.2.17 Live cell imaging 
H295R cells were transfected with non-targeting control and NEFM siRNA 
and IncuCyte Kinetic Live Cell Imaging System (Essen BioScience) was used 
to measure live cell growth at 37°C and 5% CO2 in 5 wells per treatment over 
72 hours. 
After plating 105 cells per well in a 24 well plate, the antibiotic-free growth 
media has been replaced by media with 10nM of Si-RNA (or non-targeting in 
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controls) and the plate immediately placed in in vitro live-cell imaging system 
(Incucyte).  The measurement of the occupied area (% confluence) of cell 
images over time monitors cell proliferation.  As cells proliferate, the 
confluence increases.  
 
2.2.18 Colony formation assay 
The colony formation assay (or clonigenic assay) helps evaluating the ability 
of a single cell to generate a colony of 50 or more cells (or progeny) after any 
treatment (drugs, radiation, genetic modifications).  
 A clonigenic experiment has three steps: 1) cells treatment, 2) preparation of 
single cell suspension, counting and plating a known and equal number of 
cells in six wells plate and, 3) fixing and staining colonies following a relevant 
incubation period (3-4 weeks for H295R cells). 
For our experiments, H295R were transfected with shRNA for NEFM in 24 
well plates by using Lipofectamine 3000 as described before.  After 48 hours 
incubation, cells were washed with PBS, trypsinized to obtain single cell 
suspension and counted at hemocytometer.  Three hundred cells were 
seeded per well (every treatment had triplicates) and incubated at 37°C in a 
5% CO2 environment for 3 weeks.  Media was changed every week.  After 
this incubation period, the cells were fixed and stained: the media was 
aspirated from each well and the cells washed with PBS twice.  The colonies 
were fixed on ice with ice-cold methanol for 10 minutes. The methanol was 
aspirated and the cells washed again with PBS.  The staining was performed 
with 0, 1% (w/v) crystal violet in dH2O left for 30 minutes. The crystal violet 
was then removed the wells washed with dH2O.  After drying overnight the 
plates were photographed and the individual colonies counted using Image J. 
2.2.19 Escherichia coli (E. coli) Transformation  
50 µl of One Shot® TOP10 E. coli Competent Cells (Invitrogen, USA) was 
thawed on ice and mixed with about 100 ng of plasmids which carried the 
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gene for Ampicillin resistance.  After 15 min incubation on ice the cells 
underwent a 42°C heat shock in water bath for 45 seconds, followed by 2 min 
incubation on ice.  After this 250 µl of SOC medium was added and the cells 
were incubated at 37°C for 1 h shacking at 250 rpm.  Finally, the cells were 
pelleted by centrifugation at 14,000 rpm for 30 seconds.  The cells were re-
suspended and seeded in a pre-warmed LB Agar plate with ampicillin.  50 µl 
of nuclease-Free Water was used as negative control.  The plates were 
incubated at 37°C overnight.  The next morning, 3-5 single colonies were 
picked for miniprep and maxiprep from the positive plate.  
2.2.20 Miniprep  
A single colony of E. coli from the seeded plate was picked and transferred to 
5 ml of LB broth medium supplemented with ampicillin and incubated at 37°C 
overnight -shaking at 250 rpm. 4.5 ml of the suspension was used for 
miniprep to obtain enough plasmid to be sequenced and the other 0.5 ml was 
stored at 4°C for maxiprep.  The QIAprep Spin Miniprep Kit (Qiagen, UK) was 
used for miniprep according to the manufacturer’s instructions.   
In brief, the bacteria were pelleted by centrifugation and resuspended in buffer 
P1 (Resuspension Buffer: 50mM Tris-Cl, pH 8.0, 10mM EDTA, 100ug/mL 
RNase A), plus buffer P2 (Lysis Buffer: 200mM NaOH, 1% SDS) and buffer 
P3 (Neutralization Buffer: 3.0M potassium acetate, pH 5.5).  The mixture was 
centrifuged and the supernatants moved to the QIAprep spin column and 
centrifuged.  The plasmid DNA in the spin column was washed using buffer 
PE, then eluted in RNase free water. The concentration of the plasmid DNA 
was measured at NanoDrop. A sample of each miniprep was sent for Sanger 
sequencing to select the right colony with expected sequence of plasmid 
DNA.  
2.2.21 Maxiprep  
The saved bacterial cell suspension from the original colony was added to 
500 ml of LB broth containing ampicillin (final concentration 100 µg/mL) and 
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incubated at 37°C for maximum 16 h at 250 rpm.  The next day, the bacteria 
suspension was centrifuged at 3200 rpm for 1 h at 4°C and maxiprep was 
performed using the EndoFree Plasmid Kits (Qiagen, UK) according to the 
manufacturer’s instructions.  
In brief, the bacterial pellet was suspended in buffer P1, buffer P2 and chilled 
buffer P3.  The lysate was poured into a QIAfilter Cartridge and kept at room 
temperature for 10 min.  The cell lysate was then pressed and filtered. After 
that, buffer ER was added (1:10) and incubated on ice for 30 min.  
Subsequently, the cell lysate was poured into a QIAGEN-tip 500 column with 
an equilibrated membrane where the plasmid DNA attached after the lysate 
went across by gravity. The column was washed with buffer QC twice and the 
DNA was eluted in buffer QN, and precipitated by isopropanol and centrifuged 
at 3200 rpm for 1 h at 4°C.  The DNA pellet was washed by 70% ethanol once 
and air-dried until the residual ethanol evaporated. The DNA pellet was eluted 
in endotoxin-free RNase free water and nanodropped to determine the DNA 
concentration. 
 
2.2.22 Polymerase chain reaction (PCR)  
Most of the polymerase chain reaction (PCR) in this study used the following 
fast PCR reaction system and program as suggested by the protocol (Applied 
Biosystems, USA):  
Fast PCR reaction system:  
1. Forward primer (5 µM) 2 µl;  
2. Reverse primer (5 µM) 2 µl;  
3. Human adrenal or blood sample template (50-200 ng) 6 µl;   
4. AmpliTaq Gold®Fast PCR Master Mix (Applied Biosystems, USA) 10 µl, 
UP (2×).  
 
Fast PCR program:  
1. 95 ºC 10 min to start the enzyme;  
2. 35 Cycles of the following steps:  
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1> 96 ºC 3 seconds for denature;  
2> Primer Melting Temperature for 3 seconds;  
3> 68ºC 5 seconds for extension;  
 
3. 72 ºC 10 seconds for Final elongation. 
 
 
For the KCNJ5 gene sequencing, the regions including the selectivity filter 
and inner helix were sequenced using the following sets of primers: 
 
Set 1 forward primer: 5’-TTG AAA ACC TCA GTG GCT TC-3’ 
Set 1 reverse primer: 5’-GCA GCT GAG CCT GAG ACA TC-3’ 
Set 2 forward primer: 5’-GAT GGT GTC TTT TTA ACT CAA AGC-3’ 
Set 2 reverse primer: 5’-CTG AGG AGG ACA AAG CGC C-3’ 
Set 3 forward primer: 5’-ATG GCT GGC GAT TCT AGG AAT GCC-3’ 
Set 3 reverse primer: 5’-TCA CAC CGA GCC CCT GGC CTC C-3’. 
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Chapter 3: Role of NEFM, a ZG-selective gene, in human adrenal  
 
3.1 Abstract  
Heterogeneity among APAs has been highlighted by the discovery of somatic 
mutations.  Frequent KCNJ5 mutations are usually present in large ZF-like 
APAs; mutations in CACNA1D, ATP1A1, ATP2B3 and CTNNB1 had been 
found in small APAs with ZG-like histological features.  Microarray 
comparison of KCNJ5 mutant versus wild-type APAs revealed significant 
differences in transcriptomes.  NEFM, one the neurofilament subunits and a 
dopamine receptor D1R interacting protein, was 4-fold-upregulated in KCNJ5 
wild-type ZG-like vs KCNJ5 mutant ZF-like APAs, and 14-fold more 
expressed in normal ZG vs ZF.  
Immunohistochemistry confirmed selective expression of NEFM in ZG from 
adjacent adrenal cortex and in ZG-like APAs.  
Silencing NEFM in H295R cells increased basal aldosterone secretion and 
cell proliferation.  Moreover, it also amplified aldosterone stimulation and 
inhibition in response to D1R agonist fenoldopam and antagonist SCH23390, 
respectively.  NEFM co-immunoprecipitates with D1R and its expression is 
stimulated by fenoldopam, thus suggesting that it plays a role in preventing 
D1R accumulation to the plasma membrane.   
Immunohistochemistry for D1R differed between the two APA subtypes. In 
ZG-like APAs was mainly intracellular, membranous in ZF-like APAs. 
Aldosterone secretion in response to fenoldopam in primary cells from ZF-like 
APAs was significantly higher than in cells from ZG-like APAs.  
In conclusion: (1) NEFM is a negative regulator of aldosterone production and 
cell proliferation; (2) it prevents D1R trafficking to plasma membrane; (3) its 
down-regulation in ZF-like APAs may contribute to a D1R/D2R imbalance 
underlying variable pharmacological responses to dopaminergic drugs among 
patients with APAs. 
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3.2 Introduction 
Transcriptome comparison between human adrenal ZG and ZF found 
unsuspected genes up-regulated -up to 25-fold- in ZG vs ZF 3.  
Of these, 7 genes were more than ten-fold up-regulated (LGR5, VSNL1, 
ANO4, NEFM, VCAN, DACH1 and NR4A2), but only VSNL1 and NR4A2 have 
previously been investigated in zona glomerulosa (Bassett et al. 2004; 
Williams et al. 2012).  NEFM expression and function in the adrenal ZG has 
been further investigated.  
 
Its expression was 14.8 fold up regulated in ZG vs ZF (p=9.16-12) and 3.2 fold 
down-regulated in overall APA vs ZG (p=1.38-03).  Of note, the two APA 
subtypes showed different expression levels: NEFM expression was 3.96 fold 
down-regulated in KCNJ5 mutant APAs in comparison to wild type (p=4.35-03).  
 
NEFM is one of the subunits forming the Neurofilament (NF), the type IV 
intermediate filament of mature neurons, one of the most abundant proteins in 
the nervous system.  Instead of other intermediate filaments types expressed 
in different cell types that are homo-polymers, NFs are hetero-polymers 
composed of four subunits: NEFL, NEFM, NEFH (classified according to their 
molecular weight), plus alpha-internexin in the central nervous system or 
peripherin in peripheral nervous system. 
 
The four subunits have a common structure: a conserved central-helical rod 
region, and non-helical regions, the head domain at the N-terminus and a tail 
of variable length at the C-terminus.  The rod domain contains highly 
conserved motifs, while head and tails are less conserved.  The head domain 
is rich for serine and threonine.  The tail domain is the distinctive feature of NF 
proteins.  NEFL tail is short and rich in glutamic acid, whereas it is longer in 
NEFM and NEFH, and contains not only several glutamic acid residues but 
also multiple repeats of’ phosphorylation sites lysine–serine–proline (KSP) 
(Perrot et al. 2008). 
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The complex regulation of head and tail phosphorylation distinguishes NF 
subunits from other intermediate filaments, beyond the structural role as 
cytoskeletal proteins.  Phosphorylation controls turnover, subunit 
polymerisation and tail extension, but other functions are expected. 
 
 NF subunits explicate extra-cytoskeletal roles in the neuronal synapses as 
receptors-interacting proteins, while recent studies have showed that NEFM, 
NEFL and NEFH can also be considered onco-suppressor genes in different 
cancer types, in which their epigenetic silencing affects cell proliferation, and 
correlates with aggressiveness and prognosis (Calmon et al., 2015; Peng et 
al., 2015; Shen et al., 2016; Wang et al., 2015). 
 
Regarding the synapses, the previous conception as simple NF degradation 
site has been overtaken by the finding that synaptic NF proteins constitute a 
pool with different features in comparison to those expressed in other regions 
of the neurons (Yuan et al. 2015; Yuan & Nixon 2016). 
First of all, NF proteins in synapses are oligo- or monomeric and can be either 
transported in axons or locally synthesized.  They are more abundantly 
present in the post-synaptic density rather than the presynaptic terminal. So 
far NEFL and NEFM synaptic roles have been elucidated as for their 
interaction with different neurotransmitter receptors. 
 
NEFL interacts directly with the C-terminus of NR1, a subunit of N-methyl-d-
aspartate (NMDA) receptor highly concentrated in postsynaptic membranes of 
glutamatergic synapses.  Co-expression of NEFL with NR1 increases surface 
abundance of NR1 by 20% and reduces its ubiquitination process, thus 
facilitating NMDA receptor trafficking into the plasma membrane and 
contrasting its degradation. (Ehlers et al. 1995; Ehlers et al. 1998)  Moreover, 
NEFL binds to protein phosphatase-1 (PP1), which can affect the 
phosphorylation state of NF proteins and NR1 (Terry-Lorenzo et al. 2000). 
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NEFM is abundantly present in the synaptic NF population, and it is 
characterized by lower phosphorylated state if compared to other neuron cell 
regions.  In 2002 Kim et al. found, by using a yeast-two-hybrid screening 
approach, that NEFM directly and specifically interacts with the cytoplasmic 
loop of D1R, one of the dopamine receptors highly expressed and localised in 
the postsynaptic density of dopaminergic neurons.  
Co-expression of NEFM and D1R in HEK293 cells caused a 50% reduction of 
the receptor binding and of the consequent cAMP synthesis induced by D1R 
activation. 
It also reduced D1R localization at the cell surface and promoted its 
cytoplasmic accumulation.  Functionally, co-expression of NEFM with D1R 
reduced the agonist-induced desensitization of D1R.  NEFM and D1R 
localized in the rat frontal cortex. NEFM-KO mice brains showed a reduction 
in D1R expression (Kim et al. 2002). 
 
More recently, the NEFM/D1R interaction at synaptic level was more deeply 
investigated in an animal model.  In wild-type mice, NEFM co-localizes with 
the D1R in synaptic densities.  The specific deletion of NEFM, but not of 
NEFL or NEFH subunits, amplified the D1R-mediated motor responses to 
cocaine and caused the redistribution of postsynaptic D1R to the plasma 
membrane from the endosome recycling compartment (Yuan et al. 2015). 
 
Further evidence that NF proteins are correlated to D1R comes from animal 
models of drug addiction, such as cocaine or nicotine, involving the release of 
dopamine and increasing its synaptic concentrations in the mesolimbic 
system.  In these animals drugs affect NF proteins expression.  
More in detail, in one study NEFL, NEFM and NEFH were decreased 15-50% 
by chronic administration of morphine or cocaine in rats (Beitner-Johnson et 
al. 1992), but more recently it has been found that in the synaptosomal 
fractions NEFM increases after administration of D1R binding cocaine in rats 
(Kovacs et al. 2010). 
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The response to antipsychotics acting on D1R also depends on genetic 
variances of NEFM (Strous et al. 2007). 
A further evidence of NEFM/D1R interaction comes from the D1R knockout 
mouse in which NEFM expression in the brain was suppressed, while all the 
other NF subunits were not affected (Stanwood et al. 2005). 
 
NF proteins expression is deregulated in cancer: the three NF subunits are 
epigenetically inactivated (mainly by DNA methylation) in several tumors such 
as breast, pancreas, gastric, and colon cancer.   
Their epigenetical silencing correlates with the prognosis and progression and 
staging of the disease.  One study found that overexpression of NEFH 
reduces cell proliferation and stops cells cycle progression at Go/G1 phase 
transition, with a reduction in migration and invasion in breast cancer cells 
(Calmon et al. 2015). 
Another epigenetic mechanism involved in silencing NF subunits is the 
expression of micro-RNA. NEFL is as instance silenced in aggressive brain 
cancer and in head and neck carcinomas because of the overexpression of 
miR-25 (Peng et al. 2015). 
More than one pathway can be involved: silencing NEFL in a lung cancer 
derived cell line increased invasion and migration via inhibition of the NF-kB 
pathway (Shen et al. 2016). 
DNA methylation of the NEFH promoter and down-regulation of expression 
activates the AKT/b-catenin pathway in renal carcinoma cells. 
NEFL silencing in head and neck cancer causes an activation of mTOR 
signaling (Dubrowinskaja et al. 2014). 
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3.3 Study design 
In order to investigate the role of NEFM in the adrenal, we have characterized 
its protein expression in human adrenals and co-localized NEFM with D1R 
staining. We also investigated the function of NEFM on adrenal 
steroidogenesis and its effect on the cell proliferation.  For its known 
interaction with synaptic D1R we have investigated the functional interaction 
between NEFM and D1R by evaluating co-localisation, co-immuno-
precipitation, D1R cellular trafficking in relation to NEFM expression and 
aldosterone response to drugs targeting D1R in both H295R cells and primary 
cells from the two different APA subtypes. 
3.4 Specific Methods 
3.4.1 Antibodies testing 
The rabbit polyclonal anti-D1R antibody (Sigma) was tested for specificity at 
IHC using a competing peptide (Sigma). The rabbit polyclonal anti-NEFM 
antibody was tested in lysates of nontargeting and NEFM-specific siRNA-
transfected H295R.  Kidney and brain slides were used as positive control at 
IHC, respectively. 
 
3.4.2 Co-immunoprecipitation  
500 µg of whole-cell lysates protein with a final volume of 1 ml were pre-
cleared by incubation with 10 µl of Protein A/G PLUS-Agarose (Santa Cruz, 
sc-2003) at 4 °C for 1 hour followed by centrifugation at 4 °C for 1 min at 
4000 rpm. The supernatant was subjected to immunoprecipitation by the 
addition of 1 µg of mouse anti D1R (Santa Cruz, sc-33660) antibodies and 
incubated overnight at 4 °C, followed by incubation with Protein A/G PLUS-
Agarose for 2 h.  After washing with lysis buffer and buffer A (50 mM Tris and 
0.1 mM EGTA) twice, the beads were incubated in 2 × SDS loading buffer at 
room temperature, then transferred to a SpinX tube and centrifuged for 3 
minutes at 14000 rpm.  The eluent was collected and reducing agent beta-
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mercaptoethanol was added.  The samples were resolved by SDS-PAGE and 
subjected to Western blot analysis, as previously described.   Rabbit Anti 
NEFM 1:500 (Sigma) was used to probe the membrane.  
3.4.3 shRNA 
In order to visualize cells at confocal microscopy, we have transfected cells 
with shRNA plasmid expressing eGFP.  pLVTH was a gift from Didier Trono 
(Addgene plasmid # 12262).  shRNA sequence targeting NEFM was cloned 
into pLVTH plasmid using Q5 site directed mutagenesis kit (NEB) and primers 
(5’ATCCGTTGCGCTCCACCGTGATGTTTTTTGGAAAAGCTTATCGATACC- 
3’ and 3’ –
ATCAATTGCGCTCCACCGTGATGTGGGGATCTGTGGTCTCATAC- 5’).  
Stem loop sequence used was sense 5- ACAUCACGGUGGAGCGCAA- 3’ 
and 5’- UGUAGUGCCACCUCGCGUU- 3’. Loop sequence used was 5’-
TTGATATCCG-3’.  Sanger sequencing verified the shRNA sequence 
insertion and Lipofectamine 3000 was used to transfect cells. 
3.4.4 Mitochondrial staining with MitoTracker Orange CMTMRos 
Cells were grown and transfected with shRNA on coverslips.  After 48 hours 
the media was removed and replaced by pre-warmed (37°C) complete media 
containing MitoTracker probe (at 250 nM).  The incubation time was 30 
minutes at 37°C and 5% CO2.  After staining, the cells were washed in PBS 
three times (5 minutes each), and fixed with 4% paraformaldehyde for 10 
minutes.  After fixation, the cells were washed three times in PBS and cover 
slips were mounted on slides using VECTASHIELD Antifade Mounting 
Medium with DAPI (H-1200, Vector Laboratories). MitoTracker Orange 
CMTMRos has an emission of 554 nm and excitation of 576 nm. 
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3.5 Results 
3.5.1 Microarray  
Microarray comparison of ZG vs ZF from 21 humans found that NEFM was 
the fourth most up-regulated gene (14.8 Fold-change, p= 9.16-12). 
When the transcriptome of ZF-like, KCNJ5-mutant APAs was compared to 
ZG-like, KCNJ5 wild-type APAs, NEFM resulted to be the fourth most down-
regulated gene in the former (-3.96 Fold-change, p=4.35-03, Figure 3.1) . 
 
 
 
 
 
Figure 3.1: Representative RMA values of NEFM automatically clustered 
ZF, ZG and APA separately.  RMA: Robust Multichip Average. T: Tumor 
(Aldosterone-Producing Adenoma). ZF: Zona Fasciculata. ZG: Zona 
Glomerulosa. Group legend: FM: ZF-Mutant KCNJ5. FP: ZF-
Phaeocromocytoma. FW: ZF- wild-type KCNJ5. GM: ZG-Mutant KCNJ5. 
GP: ZG-Phaeocromocytoma. GW: ZG-KCNJ5 wild-type. TM: Tumor -
mutant KCNJ5. TW: Tumor- Wild-type KCNJ5. 
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The microarray results were validated and confirmed by qPCR performed on 
LCM samples (Figure 3.2). 
 
 
 
 
 
 
Figure 3.2: NEFM qPCR validation of microarray findings performed on 
LCM samples from ZG, ZF and APAs of 7 patients with 
phaeocromocytoma, 7 patients with KCNJ5 mutant, and 7 patients with 
KCNJ5 wild-type APAs. Results are expressed as Mean and S.E.M of 2^-
dCT. Multiple t-tests were applied. 
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3.5.2  Antibodies testing 
The rabbit polyclonal anti-D1R antibody (Sigma) was tested for specificity at 
IHC using a competing peptide (Sigma). The rabbit polyclonal anti-NEFM 
antibody was tested in lysates of nontargeting and NEFM-specific siRNA-
transfected H295R. 
The disappearance of D1R staining after the competing peptide experiment 
and of NEFM band in silencing experiments allowed us to confidently rely on 
the specificity of these two commercial antibodies.  
Kidney and brain slides were used as positive control at IHC, respectively.  
IHC of D1R showed staining mainly in proximal tubules but not in the 
glomeruli.  IHC of NEFM showed that neuronal perikarya and axonal fibers 
were all NEFM-positive (Figure 3.3). 
No primary antibody control was performed by incubating tissue with the 
antibody diluent alone and no primary antibody, followed by incubation with 
secondary antibodies and detection reagents. The absence of staining 
confirmed that the staining from primary antibody experiment is produced 
from its detection of the antigen and not by the detection system or the 
specimen (Figure 3.4). 
 
 
  
 
 
 
 
73 
 
Figure 3.3: Antibodies validation.  Panel A: IHC analysis of paraffin-
embedded APA slides, using rabbit anti D1R (Sigma) pre-incubated 
without (Left) and with blocking Peptide (100X molar excess, Right). The 
staining disappears in presence of the blocking peptide. 
 Panel B: IHC of D1R of paraffin-embedded human kidney slides, used 
as positive control, at two magnifications.  The staining was mainly in 
proximal tubules but not in the glomeruli.  Panel C 1: IHC of NEFM of 
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paraffin-embedded human brain slides, used as positive control, at two 
magnifications. Neuronal perikarya and axonal fibers are all NEFM-
positive. Panel C 2: Western blot analysis of lysates from H295R cells 
transfected with either nontargeting siRNA or NEFM specific siRNA. 
Downregulation of signal from the anti-NEFM antibody confirms target 
specificity. Anti GAPDH was used as loading control. 
 
 
 
 
 
Figure 3.4: No primary antibody control of paraffin-embedded adrenal 
slides from adjacent adrenal gland next to a phaeocromocytoma.  
Tissue is incubated with the antibody diluent alone and no primary 
antibody, followed by incubation with secondary antibodies and 
detection reagents. This ensures that staining is produced from 
detection of the antigen by the primary antibody and not by the 
detection system or the specimen. 
 
 
 
 
 
 
 
  
 
 
 
 
75 
 
 
 
3.5.3 NEFM protein expression in AAG and APA 
NEFM protein was highly and selectively expressed in the ZG of adjacent 
adrenal glands (AAG) next to an APA or AAG next to a Phaeocromocytoma 
(Figure 3.5 panel A).  In the positive control sections (human cerebral cortex 
sections), NEFM staining was observed in the neuron bodies and axons as 
expected (Figure 3.3). In the adrenal ZG the staining was cytoplasmic. 
Cytoplasmic staining of NEFM was found in APAs (Figure 3.5, panel B).  ZG-
like APAs appeared to express higher levels of NEFM protein in comparison 
to ZF-like APAs (see also Figure 3.7). 
 
We also compared NEFM staining with other ZG/ZF markers including the ZG 
markers, CYP11B2 and KCNJ5, and the ZF marker, CYP11B1. The 
distribution of NEFM appeared more ZG-selective of all the ZG markers 
(Figure 3.6). As previously noted, CYP11B2 was patchy in the ZG. 
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Figure 3.5: Immunohistochemistry (IHC) of NEFM in formalin-fixed paraffin 
embedded human adrenal sections.  
A, IHC of NEFM in adjacent normal adrenal cortex. NEFM is highly expressed 
in zona glomerulosa (ZG) cell’s cytoplasm.   
B, IHC of NEFM in APAs. NEFM is more expressed in ZG-like than ZF-like 
APAs i) and iv) whole slide scanned images Ii), iii), v), vi) zoomed insets of 
left panels.  
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Figure 3.6: IHC of NEFM, ZF marker CYP11B1, and ZG markers C B, IHC of 
NEFM in APAs. NEFM is more expressed in ZG-like than ZF-YP11B2 and 
KCNJ5, in serial sections from adjacent normal cortex in a patient with APA. 
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Figure 3.7:  Immunohistochemistry (IHC) of NEFM in formalin-fixed 
paraffin-embedded APAs sections.  Three different genotypes (KCNJ5, 
Cav1.3 and beta-catenin mutants) are shown, differing in terms of NEFM 
expression levels. ZF-like, KCNJ5 mutant APAs have very low NEFM 
expression.  ZG-like, Cav1.3 and beta-catenin mutant APAs express 
higher NEFM protein levels.  
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3.5.4 NEFM expression in H295R and HEK293 cells: Immunofluorescent 
staining. 
We have evaluated NEFM expression pattern in H295R cells and compared it 
to HEK293 by confocal microscopy.  The latter expresses several neuronal 
markers, including NEFM itself (a neuronal origin of this popular cell line has 
been in fact hypothesized).   The cells were counter stained with plasma 
membrane marker WGA and nuclear staining DAPI.  We can notice a different 
NEFM staining pattern in the two cell lines: in H295R cells it is not only 
cytoplasmic but also nuclear and not organized in filaments resembling 
cytoskeletal proteins (Figure 3.8), whereas in HEK293 cells NEFM protein 
appears to be localized in the cytoplasm only and to assemble in filaments 
(Figure 3.9).  
 
Figure 3.8. Confocal microscopic images of immunofluorescent staining 
showed endogenous NEFM staining (green), plasma membrane (red), 
nuclei (blue) and the overlay of them in the same sight field in H295R 
cells.  NEFM staining is cytoplasmic but also nuclear and not organized 
in filaments resembling cytoskeletal proteins. Pictures are 
representative of three fields.  
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Figure 3.9:  Confocal microscopic images of immunofluorescent 
staining showed endogenous NEFM staining (green), plasma membrane 
(red), nuclei (blue) and the overlay of them in the same sight field in 
HEK293 cells. NEFM staining is cytoplasmic and more condensed. 
Pictures are representative of three fields. 
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3.5.5 Silencing NEFM in H295R cells by siRNA and shRNA 
H295R cells silenced by 10 nM Si-NEFM (ACAUCACGGUGGAGCGCAA) for 
48 hours had a reduced NEFM expression both at mRNA and protein level in 
comparison to non-targeting siRNA (UGGUUUACAUGUCGACUAA). 
The single oligonucleotide and the concentration were chosen after 
optimization and comparison to the other 3 single oligonucleotides included in 
the pool (Figure 3.10). 
 
Comparing to the non-targeting control, the NEFM mRNA was decreased by 
51% (N=6, P< 0.0001; Figure 3.11). This change resulted in a significant 38% 
increase in aldosterone (N=12, from 102 to 140 pM/ug protein, P<0.05, Figure 
3.14)  
The mRNA level of aldosterone synthase, CYP11B2, was decreased by 57% 
(N=6, P<0.01, Figure 3.12), and the CYP11B2 transcription factor NR4A2 
mRNA levels were consistently decreased by 64% (N=6, P<0.05; Figure 
3.13). 
 
Analogous results were achieved by shRNA plasmid transfection.  GFP- 
tagged shRNA was used to identify the transfected cells at the microscope 
and analyse fluorescent staining for D1R and other proteins. 
At 48 hours from transfection, shRNA caused a decrease of NEFM mRNA 
levels by 59% (N=3, P<0.05, Figure 3.15 panel A). Consistently with siRNA 
results, it caused a reduction of CYP11B2 mRNA levels by 55% (N=3, 
P<0.05, Figure 3.15, panel B) and an increase of basal aldosterone levels by 
23% (N=4, P<0.05, Figure 3.15, panel C). 
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Figure 3.10: Effect of single RNA oligonucleotides (numbered from #1 to 
#4) targeting NEFM on NEFM mRNA expression in H295R cells at 48 
hours. Different concentrations (from 5 to 25 nM) had been tested. We 
have chosen oligonucleotide #2-sequence reported in the paragraph- at 
10 nM as it gave the best mRNA knock-down. NT: non targeting. Results 
are expressed as geometric mean values with SEM and compared using 
multiple Student t test vs NT. The significance level of P<0.05 (*) was 
considered to indicate statistical significance. 
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Figure 3.11: Effect of Si-NEFM on NEFM mRNA expression in H295R 
cells. 10 nM of Si-NEFM transfection decreased the NEFM expression by 
51%, comparing to 10 nM of non-targeting transfection (P<0.001). 
Results are expressed as geometric mean values with SEM and 
compared using the 2-sided Student t test. The significance level of 
P<0.05 was considered to indicate statistical significance. 
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Figure 3.12: Effect of Si-NEFM on CYP11B2 mRNA expression in H295R 
cells.  10 nM of Si-NEFM transfection decreased the NEFM expression 
by 51% comparing to 10 nM of non-targeting transfection (P<0.01). 
Results are expressed as geometric mean values with SEM and 
compared using the 2-sided Student t test. The significance level of 
P<0.05 was considered to indicate statistical significance. 
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Figure 3.13: Effect of Si-NEFM on NR4A2 mRNA expression in H295R 
cells. 10 nM of Si-NEFM transfection decreased the NEFM expression by 
51%, comparing to 10 nM of non-targeting transfection (P<0.05).  Results 
are expressed as geometric mean values with SEM and compared using 
the 2-sided Student t test. The significance level of P<0.05 was 
considered to indicate statistical significance. 
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Figure 3.14: Effect of Si-NEFM on aldosterone production in H295R cells. 
10 nM of Si-NEFM transfection increased the aldosterone production by 
38% in comparison to 10 nM of non-targeting (P<0.05).  Aldosterone 
production was normalized by total protein from the same wells.  
Results are expressed as geometric mean values with SEM and 
compared using the 2-sided Student t test. The significance level of 
P<0.05 was considered to indicate statistical significance. 
  
non targeting siNEFM
0
50
100
150
200
al
do
st
er
on
e 
(p
M
)/p
ro
te
in
 (u
g) * p<0.05*
  
 
 
 
 
87 
 
 Figure 3.15: effect of NEFM-shRNA on NEFM, CYP11B2 mRNA and 
aldosterone levels (panels A, B and C, respectively) in H295R at 48 
hours from transfection. Results are expressed as geometric mean 
values with SEM and compared using the 2-sided Student t test. The 
significance level of P<0.05 was considered to indicate statistical 
significance. 
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3.5.6 NEFM affects adrenal cells proliferation. 
The top hit genes up-regulated in ZG vs ZF studied so far (LGR5, VSNL1, 
DACH1) have been shown to regulate apoptosis and cell proliferation.  
Moreover, as mentioned before, NEFM and other NF subunits are silenced in 
cancer and play a role in cell proliferation.  Therefore, we have investigated 
the effects of knocking down NEFM in H295R cells on cell confluence and 
proliferation with two different techniques. 
 
After plating 105 cells per well in a 24 well plate, the antibiotic-free growth 
media has been replaced by media with 10nM of Si-RNA (or non-targeting in 
controls) and the plate immediately placed in in vitro live-cell imaging system 
(Incucyte).  The measurement of the occupied area (% confluence) of cell 
images over time monitors cell proliferation.  As cells proliferate, the 
confluence increases.  
Kinetic live-cell imaging of si-NEFM transfected cells directly quantified a 15 ± 
1.3% increase in the proliferation of H295R cells (N=4, P< 0.0001, Figure 
3.16). 
 
Consistently, an increase in cell proliferation and clonigenic ability of H295R 
after silencing NEFM was confirmed by using a different silencing technique 
and by a different assay, the colony-forming assay. 
At 3 weeks from transfection of shRNA, the number of colonies was 
significantly higher in H295R cells transfected with shRNA in comparison to 
empty vector (ev) (N=3, 162 vs 93 colonies, P<0.05, Figure 3.17). 
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Figure 3.16:  Effect of silencing NEFM on cell proliferation evaluated at 
Incucyte. Calculation of cell confluence was performed every 2 hours 
and for 72 hours.  Kinetic live-cell imaging of Si-NEFM transfected cells 
directly quantified a 15 ± 1.3% increase in the proliferation of H295R 
cells (P< 0.0001). Results are expressed as mean values with SEM and 
compared using the 2-sided Student t test. The significance level of 
P<0.05 was considered to indicate statistical significance. 
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Figure 3.17: Effect of silencing NEFM by shRNA At 3 weeks from 
transfection of shRNA, the number of colonies was significantly higher 
in H295R cells transfected with shRNA in comparison to empty vector 
(ev) (162 vs 93 colonies, data expressed as mean ± SEM). 
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3.5.7 Silencing NEFM affects mitochondrial membrane potential 
In neurons NF interacts with mitochondria and regulate both localisation and 
membrane potential.  Positioning of mitochondria is important in axons where 
high amount of ATP is required but these organelles also buffer Ca2+ to 
regulate neurotransmission.  NF binding to mitochondria affects their 
metabolic activity by reducing their mobility. 
 
Mitochondrial membrane potential changes can affect cell proliferation since 
this is the main driver for cytoplasmic Ca2+ to entry into the mitochondria and 
stimulate cell proliferation (Nunez et al., 2006).  Therefore we have 
hypothesized that silencing NEFM stimulates proliferation by affecting 
mitochondrial membrane potential and performed a staining with MitoTracker 
Orange CMTMRos in adrenocarcinoma cell line H295R, whose signal 
intensity is directly proportional to the mitochondrial membrane potential. 
 
At 48 hours from shRNA transfection, the MitoTracker Orange CMTMRos 
staining was more intense in GFP-positive, shRNA transfected cells, in 
comparison to not transfected cells in the same field, thus indicating an 
increased mitochondrial membrane potential (which could increase Ca2+ 
intake) and mitochondrial metabolic activity (Figure 3.18). 
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Figure 3.18: Mitochondrial staining with MitoTracker Orange CMTMRos 
in H295R cells transfected with GFP-tagged shRNA.  The MitoTracker 
Orange CMTMRos staining appears to be more intense in the GFP-
positive transfected cell (zoomed in the small square), suggesting that 
in absence of NEFM the mitochondria are more depolarized and likely to 
uptake Ca2+ and stimulate proliferation.  
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3.5.8 NEFM expression levels correlates with D1R subcellular 
localisation in the two APA subtypes  
NEFM interacts with D1R in the neuronal synapses, where it mediates its 
internalization in response to the agonist. NEFM knockout mice have 
amplified D1R-mediated motor responses to cocaine. These evidences 
suggest that the expression levels of NEFM could affect D1R subcellular 
localization; plasma membrane trafficking and consequently any D1R 
mediated biological response. 
Our microarray analysis showed that NEFM expression levels differ between 
the two APA subtypes, and it resulted to be higher in KCNJ5 wild-type, ZG-
like than in KCNJ5 mutant, ZF-like APAs. 
We have therefore hypothesized that the two subtypes would differ also in 
terms of D1R expression pattern and aldosterone response to D1R activation 
due to agonist (fenoldopam) binding. 
 
To answer the first question, we have compared the D1R staining pattern at 
IHC in formalin-fixed, paraffin-embedded sections of the two APAs subtypes. 
 
We have found that D1R protein expression in ZG-like, KCNJ5 wild-type 
APAs, which express high NEFM levels, is mainly cytoplasmic, whereas in 
ZF-like, KCNJ5 mutant APAs D1R protein is mainly localised on plasma 
membrane, thus suggesting that more D1R is available on cell surface (Figure 
3.19). 
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Figure 3.19: : IHC for D1R of paraffin-embedded human adrenal sections 
including ZG-like (i), ii) ,iii)), and ZF-like APAs ( iv) ,v) ,vi))  in ZG-like 
APA D1R is mainly localized in the cytoplasm. In ZF-like APAs D1R is 
mainly localized on the plasma membrane. i),iiii) scanned images. Ii), iv), 
zoomed insets of left panels.  
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Figure 3.20: NEFM (Panels A and B) and D1R (Panels C and D) staining 
in the normal adrenal cortex.  NEFM staining appears to be ZG-selective 
and cytoplasmic.  D1R appears to be expressed in the adrenal medulla 
and in the adrenal cortex although it seems to be more cytoplasmic in 
ZG and membranous in ZF. 
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3.5.9 Aldosterone response to D1R agonist fenoldopam varies in 
primary cells from two APA subtypes with different NEFM expression  
Because of the different NEFM expression levels and D1R subcellular 
localisation in the two APA subtypes, we have measured aldosterone in 
response to D1R agonist fenoldopam in primary cell cultures derived from four 
ZF-like, KCNJ5 mutant and four ZG-like, KCNJ5 wild-type APAs.  
 
After 4-6 days in culture in a 75-cm2 flasks, the cells were seeded in 24 well 
plates.  The day after seeding, cells were starved in nil media for six hours, 
and then treated with fenoldopam (at only two different doses because of the 
scarcity of cells).  After 24 hours, the media was collected and cell harvested 
in RIPA buffer.  Aldosterone was measured by HTRF assay and normalized 
per protein concentration measured by BCA, as explained in the first chapter.  
 
Primary cells from both adrenal subtypes responded to fenoldopam, but the 
stimulation by fenoldopam at maximal dose (10-7 M) was bigger in those from 
KCNJ5-mutant, ZF-like APAs (from 1±0.07 at 0 M to 1.24±0.106 at 10-8 M and 
1.38±0.103 at 10-7 M in ZG-like APA cells vs 1±0.15 at 0 M to 1.49±0.23 and 
2.28 ± 0.35 at 10-8 and 10-7 M, respectively, in ZF-like APA cells, P<0.05 at 10-
7- M). M stands for mol/L. 
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Figure 3.21: Aldosterone secretion in primary adrenal cells from ZG-
like and ZF-like APAs (n = 4 each) in response to fenoldopam.  
Each concentration was replicated 4 times within each individual 
patient samples. Aldosterone results shown here are relative to 0 M of 
treatment.  Two-way ANOVA was used to calculate overall 
significance.  The stimulation by fenoldopam at maximal dose (10-7 M) 
was bigger in KCNJ5 mutant, ZF-like APAs (P<0.05 at 10-7 M). M stands 
for mol/L. 
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3.5.10. Silencing NEFM attenuates dopamine inhibition on aldosterone 
response 
 
To further evaluate the effect of NEFM expression levels on D1R response, 
we performed drug experiments in the adrenocarcinoma cell line H295R after 
si-NEFM transfection.  We investigated aldosterone secretion in response to 
dopamine, which is known to have a D2R effect and inhibit aldosterone, but 
also treated cells with D1R agonist and antagonist and D2R antagonist 
metoclopramide. 
 
In brief, H295R cells transfected with 10 nM si-NEFM and non-targeting were 
starved for six hours at 42 hours from transfection, then treated with 
increasing doses of dopamine in presence of AngII at 10-8 M, and antioxidant 
vitamin C 0.1% for 24 hours.  Aldosterone has been normalized per protein 
concentration and all values are normalized to the aldosterone/protein 
concentration at 0 M. 
 
In non-targeting siRNA transfected cells, 10-8 M, 10-7 M and 10-6 M dopamine 
caused a reduction of aldosterone secretion by 23±4, 34±10 and 24±6%, 
respectively (p <0.05 at 10-7 M).  Silencing NEFM attenuated the expected 
dopamine inhibition of aldosterone secretion.  Dopamine did not inhibit but 
slightly stimulated aldosterone production by 13±8, 26±15 and 16±10% at 10-
8 M, 10-7 M, and 10-6 M, respectively.  The differences between si-NEFM and 
non-targeting at each dose were significant at two-way ANOVA comparison 
(10 -8 M P<0.05, 10-7 M, P< 0.001, 10-6 M P<0.05, Figure 3.22). 
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Figure 3.22: Silencing NEFM attenuates dopamine inhibition on 
aldosterone response. Dopamine inhibits aldosterone in non-targeting 
control cells (by 40%), and this effect is attenuated in si-NEFM 
transfected cells in which dopamine slightly stimulates aldosterone 
production by 13±8, 26±15 and 16±10% at 10 -8M, 10-7M, and 10-6 M, 
respectively.  The differences between si-NEFM and non-targeting at 
each dose were significant with two-way ANOVA comparison (10 -8M 
P<0.05, 10-7 M, P< 0.001, 10-6 M P<0.05).  Data shown are mean ± SEM 
and normalized to 0 M. M stands for mol/L. 
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3.5.11 NEFM inhibits aldosterone response to D1R activation. 
Since NEFM knocking-down prevented aldosterone inhibition by dopamine, 
we have investigated whether this effect was mediated by D1R or D2R.  
We have examined aldosterone response to 24 hours treatment with D1R 
selective agonist fenoldopam or antagonist SCH23390 in si-NEFM transfected 
cells and controls.  The drugs had been diluted at increasing concentrations in 
nil media containing AngII at 10-8M, Dopamine at 10-7M, antioxidant vitamin C 
0.1%.   
 
Fenoldopam increased aldosterone secretion by 23 ±13 and 17.3±12 in non- 
targeting (ns).  Silencing NEFM amplified the stimulatory effect of fenoldopam 
on aldosterone secretion by 34± 10, 51±20 and 75±28 % at 10-8M, 10-7M and 
10-6M respectively (p <0.05 at 10-6M, Figure 3.23). 
 
 
 
 
Figure 3.23: Silencing NEFM amplifies fenoldopam stimulation on 
aldosterone. Fenoldopam increases aldosterone by max 24% in controls 
cells, but this effect is amplified in si-NEFM transfected cells. 
The differences between si-NEFM and non-targeting were significant 
with two-way ANOVA comparison (10-7 M and 10-6 M P<0.05).  Data 
shown are mean ± SEM and normalized to 0 M. M stands for mol/L. 
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Treatment with D1R antagonist SCH23990 caused a slight, not significant 
decrease of  aldosterone by 13±7, 9±5  and 9±4 % at 10-8M, 10-7M and 10-6 
M, respectively, in controls.   Silencing NEFM amplifies aldosterone inhibition 
by SCH23990 (by 36±4, 37±6 and 41±4  at 10-8M, 10-7M and 10-6 M, 
respectively (P<0.05 at 10-7M and 10-6 M, Figure 3.24). 
 
 
 
 
 
Figure 3.24: Silencing NEFM amplifies D1R antagonist SCH23390 
inhibition on aldosterone secretion. SCH23390 slightly inhibits 
aldosterone in non-targeting control cells, but this effect is amplified in 
si-NEFM transfected cells in which the antagonist significantly 
decreases aldosterone production by 36±4, 37±6 and 41±4  at 10-8M, 10-
7M and 10-6 M, respectively (P<0.05 at 10-7M and 10-6 M). M stands for 
mol/L. 
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We have also questioned if NEFM silencing would affect aldosterone 
stimulation by D2R antagonist.  Hence, we have treated the cells with 
increasing doses of metoclopramide, at the same time points of the previously 
described experiments.  Metoclopramide stimulated aldosterone secretion but 
with no significant difference between si-NEFM and non-targeting (Figure 
3.25). 
 
 
 
 
 
 
 
Figure 3.25: Aldosterone response to D2R antagonist metoclopramide is 
not affected by silencing NEFM. A non-significant difference has been 
found between si-NEFM and non-targeting. Two-way ANOVA was used 
to calculate overall significance. Ns=non-significant. M stands for 
mol/L. 
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3.5.12 D1R/NEFM protein interaction 
NEFM and D1R interact in mammalian cells.  This has been demonstrated in 
mice synaptosomal fraction (by co-immunoprecipitation) and previously by 
yeast two-hybrid system (Yuan et al. 2015; Kim et al. 2002).  
 
To confirm the physical interaction between endogenous NEFM and D1R in 
H295R cells, co-immunoprecipitation assay was performed.  Monoclonal 
mouse anti-D1R (or PBS as negative control) was first used to precipitate the 
protein complexes containing D1R, and the presence of NEFM protein in 
these complexes was subsequently examined by immunoblotting with a 
polyclonal rabbit anti-NEFM antibody.  The presence of NEFM protein was 
markedly detected in the cellular lysates with IP by anti-D1R antibody, not by 
control, indicating a specific interaction of NEFM with D1 (Figure 3.26).  
 
 
 
 
 
 
 
Figure 3.26: Co-immunoprecipitation of D1R pulls down NEFM, 
confirming the interaction between NEFM and D1R in H295R.  
Monoclonal mouse anti-D1R (or PBS as negative control) was used to 
precipitate the protein complexes containing D1R, and the presence of 
NEFM protein in these complexes was subsequently examined by 
immunoblotting with a polyclonal rabbit anti-NEFM antibody.   
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3.5.13 Effects of fenoldopam on NEFM expression 
Since NEFM interacts with D1R and regulates its trafficking and plays a role in 
the agonist-induced desensitization of D1R, we evaluated the changes in 
NEFM expression at both mRNA and protein level in H295R cells after 24 
hours treatment with D1R agonist fenoldopam. 
 
Fenoldopam caused a significant 2.28 and 2.9 fold increase of NEFM mRNA 
levels at 10-7 and 10-6 M, respectively (P<0.05 at 10-7M and P<0.001 at 10-6M, 
Panel A, Figure 3.27).  We have observed the same increase at protein level 
(Panel B, Figure 3.27). 
 
Of note, the forskolin hydrophilic equivalent NKH477, which is an activator of 
adenyl cyclase therefore causing an increase in cAMP (the second 
messenger of D1R activation signaling) affected in the opposite direction the 
NEFM mRNA levels (Figure 3.29), suggesting that the mechanisms of NEFM 
up-regulation following D1R activation are cAMP independent. 
 
When treated for 24 hours with NKH477 at three different concentrations, 
H295R increased aldosterone secretion as expected (by 1.8 and 2.4 fold 
change at 10-6 and 10-5M respectively, in comparison to 0 M, P<0.0001, 
Figure 3.28).  The same treatment caused a dose-dependent decrease of 
NEFM (up to 96% at 10-5M, Figure 3.29). 
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Figure 3.27: H295R treated with fenoldopam for 24 hours increased 
NEFM mRNA expression by 230 and 280 % at 10-7M and 10-6M, 
respectively (Panel A, P<0.05 and P<0.001).  Similar increases were 
observed at protein level (Panel B). Results are expressed as geometric 
mean values with SEM and compared using the 2-sided Student t test vs 
0 M. The significance level of P<0.05 was considered to indicate 
statistical significance. M stands for mol/L. 
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Figure 3.28: H295R treated with forskolin analogue NKH477 for 24 hours 
increased aldosterone secretion by 50, 298 and 400% at 10-7M 10-6M, and 
10-5M, respectively (P<0.001). Results are expressed as geometric mean 
values with SEM and compared using the 2-sided Student t test vs 0 M. 
The significance level of P<0.05 was considered to indicate statistical 
significance. M stands for mol/L. 
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Figure 3.29: H295R treated with forskolin analogue NKH477 for 24 hours 
decreased NEFM mRNA expression by 50, 75 and 95% at 10-7M, 10-6M, 
and 10-5 M, respectively (P<0.001).  Results are expressed as geometric 
mean values with SEM and compared using the 2-sided Student t test vs 
0 M. The significance level of P<0.05 was considered to indicate 
statistical significance. M stands for mol/L. 
 
 
 
 
These results suggest that cyclic AMP-independent mechanism for D1-like 
receptor signaling are likely to be involved in NEFM gene expression 
regulation as part of the desensitization to D1R stimulation. 
 
3.5.14 KCNJ5 mutations cause a down-regulation of NEFM expression in 
both H295R and primary ZG-like cells 
The transcriptome comparison of the two APA subtypes found that NEFM is 
almost four-fold downregulated in KCNJ5 mutant ZF-like vs KCNJ5 wild-type, 
ZG-like APAs (-3.96 Fold-Change, p= 4.35-03).  
We have hypothesized that the down-regulation of NEFM expression was a 
direct effect of KCNJ5 mutations.  To verify the effects of the KCNJ5 
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mutations on NEFM expression, we overexpressed KCNJ5 in H295R adrenal 
cell line by transfection with pcDNA3.1/KCNJ5WT, pcDNA3.1/ KCNJ5T158A, 
pcDNA3.1/KCNJ5I157Del, or empty vector.  After 48 hours, cells were harvested 
in 400 ul of Trizol and RNA extracted, cDNA synthetized and qPCR performed 
for NEFM and 18s mRNA (as housekeeping gene), as described in the first 
chapter.   Whole cell lysate in RIPA buffer was used for western blotting. 
 
NEFM mRNA level decreased by 34% with KCNJ5I157Del and by 59% with 
KCNJ5T158A, in comparison to wild-type (Figure 3.30, panel A, N=8, P<0.05).  
Similar results were obtained at protein level (Figure 3.30, panel B). 
To strengthen our hypothesis of a causal correlation between KCNJ5 
genotype and down-regulation of NEFM expression (a signature of ZF-like 
APAs), and aware of the difficulties of isolating a pure ZG cells population 
from normal adrenal cortex, we have transfected primary cells from a ZG-like 
APA with the same plasmids from the previous experiment.  Since the 
transfection efficiency rate is low in primary cells, we have not performed 
qPCR but immunofluorescent staining for NEFM and taken pictures of 
transfected single cells (Figure 3.31).  
 
Similarly to what found in H295R cells, we have observed that NEFM (in red), 
highly expressed in ZG-like APAs and the derived primary cells, is highly 
expressed in cells transfected with pcDNA3.1 and pcDNA3.1/KCNJ5WT, but it 
disappeared in cells transfected with the two mutations 
(pcDNA3.1/KCNJ5T158A and pcDNA3.1/KCNJ5I157Del).  
 
We have then concluded that very low or null levels of NEFM expression 
could be considered part the “ZF-like signature”, the phenotypical changes of 
APAs carrying KCNJ5 mutations.   
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Figure 3.30: Effect of the transfection of KCNJ5 mutations on NEFM 
mRNA (panel A) and protein (panel B) levels in H295R cells.  In 
comparison to wild-type, pcDNA3.1/KCNJ5I157Del and 
pcDNA3.1/KCNJ5T158A caused a decrease of NEFM mRNA level by 34% 
and 59%, respectively (panel A, P<0.05).  Similar results were obtained 
at protein level (panel B) 
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Figure 3.31: Immunofluorescence staining for NEFM (in red), in primary 
cells from a ZG-like APAs and transfected with KCNJ5 mutations. NEFM 
disappeared in cells transfected with the two mutations 
(pcDNA3.1/KCNJ5T158A and pcDNA3.1/KCNJ5I157Del). 
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3.5.15 NEFM knock-down causes D1R localisation in the cell plasma 
membrane of H295R cells 
In view of the pharmacological and IHC results, we hypothesized that, NEFM 
silencing causes D1R permanence at plasma membrane thus impairing its 
trafficking into cytoplasm. 
We then decided to transfect H295R cells with GFP expressing shRNA and 
perform immunocytochemistry with a D1R antibody.  For limited number of 
colour channels at the fluorescence microscope we have decided not to use 
WGA as a plasma membrane marker. 
 
At immunofluorescence microscopy, NEFM knock-down by shRNA increased 
D1R localization at plasma membrane in transfected (GFP positive) H295R 
cells. In untransfected cells, the red staining was mainly cytoplasmic (Figure 
3.32).  Therefore, we concluded that the pharmacological response to D1R 
agonist or antagonist in NEFM silenced cells was due to a reduced D1R 
trafficking into the cytoplasm and possibly prolonged permanence at the 
plasma membrane level. 
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Figure 3.32: Immunofluorescence staining for D1R in H295R cells 
transfected with GFP-expressing shRNA plasmid. Green=GFP. 
Red=D1R. Blue=DAPI nuclear staining. 
NEFM knock-down by shRNA increased D1R localization at plasma 
membrane in transfected (GFP positive) H295R cells. In untransfected 
cells, the red staining was mainly cytoplasmic. 
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3.6 Discussion 
Neurofilament medium (NEFM) was the fourth of the 183 genes up-regulated 
in ZG vs ZF by at least >10-fold (LGR5, VSNL1, ANO4, NEFM, VCAN, 
DACH1, and NR4A2).  
NEFM mRNA expression was 14-fold higher in ZG vs ZF.  Moreover, NEFM 
resulted to be 4-fold downregulated in ZF-like vs ZG-Like APAs. 
Microarray data were confirmed by qPCR performed on the LCM samples.  
Consistently, IHC demonstrated that NEFM protein was highly and selectively 
expressed in human ZG and ZG-like APAs.  NEFM expression was mainly 
cytoplasmic and not organized in filaments as in neurons.  
 
NEFM is one of the subunits of NF, the type IV intermediate filament 
expressed in the nervous systems.  Other subunits are Neurofilament light 
(NEFL) and Neurofilament heavy (NEFH), named after their molecular weight, 
plus alpha-internexin in the central nervous system or peripherin in peripheral 
nervous system. 
 
Herein we report the functional studies on NEFM, which is known to be a 
D1R-interacting protein in synapsis, but it has also been reported to be 
epigenetically silenced in different cancer types and related to tumour 
progression (Dubrowinskaja et al. 2014; Calmon et al. 2015; Wang et al. 
2016).  NEFM and other NF subunits are epigenetically silenced (by 
microRNA or hypermethylation) in cancers of both neuronal and non-neuronal 
origin such as neuroblastoma and breast cancer.  Their expression levels are 
also inversely correlated to the aggressiveness and staging of the tumours.   
 
Our functional studies, using H295R as a model of aldosterone producing 
cells, found that NEFM plays a role in steroidogenesis and that silencing 
endogenous NEFM increases aldosterone secretion.  
The increase was not due to an increased synthesis of aldosterone, as we 
have observed a parallel decrease in CYP11B2 transcription, but other 
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mechanisms could explain this divergence.  It is likely that the driver to 
aldosterone secretion was post-transcriptional.  One further finding needs 
comment, namely the reduction in CYP11B2 expression associated with the 
increased aldosterone secretion consequent on silencing of NEFM.  We have 
noted aldosterone secretion and synthesis to change in opposite directions in 
previous experiments, and infer that this could be explained by regulatory 
influences downstream of transcription, for instance on cholesterol uptake into 
the inner mitochondrial membrane via the steroidogenic acute regulatory 
(STAR) protein. Although in recent years the emphasis in pathways to 
aldosterone secretion has been via stimuli to CYP11B2 transcription, earlier 
literature showed that many effects, including those of dopamine, occur within 
minutes – namely too fast for a transcriptional response (Edwards et al. 
1980). 
 
Moreover, silencing NEFM caused a marked increase in cell proliferation, as 
demonstrated by two different silencing methods (siRNA and shRNA) and by 
two different proliferation assays (live cell imaging and colony forming assay). 
 
One of the possible mechanisms unifying both increased aldosterone 
secretion and proliferation could be an altered mitochondrial function.  ShRNA 
transfected cells showed a more intense MitoTracker Orange CMTMRos 
staining.  The intensity of this dye staining is proportionate to mitochondrial 
membrane potential, which could be responsible of both increased 
aldosterone synthesis and cell proliferation. 
 
Overall, these experiments have demonstrated that NEFM, similarly to our 
previously described ZG-selective up regulated genes (LGR5, DACH1), 
inhibits rather than stimulates aldosterone and cell proliferation (Shaikh et al. 
2015; Zhou et al. 2015). 
 
Since NEFM is 4-fold downregulated in large KCNJ5 mutant, ZF-like APAs 
that are usually larger than KCNJ5 wild-type, ZG-like APAs we could 
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speculate that NEFM down-regulation plays a role in the hyperplasia of 
KCNJ5 mutant APAs. 
 
Of note, NEFM inhibits not only basal aldosterone secretion but plays a role in 
regulating dopamine inhibition. 
The physiological actions of dopamine are mediated by five G protein-coupled 
receptors (GPCRs) that are divided into two major groups: the D1 and D2 
classes of dopamine receptors. This classification is generally based on the 
observations that dopamine is able to modulate adenylyl cyclase (AC) activity.  
The D1-like receptors (D1R and D5R) activate the Gαs/olf family that stimulate 
cAMP production by AC.  The D2-like receptors (D2R, D3R, and D4R) couple 
to the Gi/o Family of G proteins and induce inhibition of AC.  
 
Dopamine is known to exert maximal tonic dopaminergic inhibition of 
aldosterone secretion, and its action seems to be mediated by D2R.   In fact, 
dopaminergic antagonists such as metoclopramide but not dopamine 
agonists, such as bromocriptine, increase aldosterone without affecting 
cortisol (Pivonello et al. 2004).   
 
Dopamine-binding sites in the human adrenal cortex are concentrated in the 
ZG and they are mainly D2R.   D1R is also expressed in the adrenal cortex, 
specifically ZG, of several mammalian species as demonstrated by IHC and 
autoradiographic or binding studies in rat or bovine adrenal cortex.  
In human adrenal cortex autoradiographic or binding studies did not identify 
any specific [3H] SCH 23390 binding sites (Amenta et al., 1994). 
 
NEFM is involved in the agonist-induced D1R desensitization in the post-
synaptic densities, where it binds endosomes formed after internalization of 
D1R following agonist binding.  D1R is retained in an internal pool within the 
synapsis and ready to be trafficked on the membrane.  This mechanism would 
balance desensitization to D1R stimulation.  In fact, in NEFM knock out mice, 
the absence of this anchoring action causes hypersensitivity to D1R agonists 
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(Yuan et al., 2015) . 
 
We have hypothesized an analogue action of NEFM in the normal ZG.  D1R 
protein expression pattern differ between ZG and ZF.  In ZG, which expresses 
high NEFM levels, D1R staining was mainly cytoplasmic, in ZF membranous. 
The cytoplasmic subcellular localization of D1R could therefore correlate to 
NEFM expression levels. 
 
In support to our hypothesis, D1R staining differs in ZG-like and ZF-like APAs.  
In ZF-like APAs, characterized by low NEFM expression levels, D1R staining 
was mainly membranous, whereas in ZG-like APAs, which show intense 
NEFM protein staining, D1R staining was mainly cytoplasmic. 
 
In addition to these histological observations, we have evaluated aldosterone 
secretion response to increasing doses of D1R agonist fenoldopam in primary 
cells from the two APAs subtypes.  Consistently, cells from ZF-like APAs have 
a bigger aldosterone response in comparison to those from ZG-like APAs, 
suggesting that D1R is more sensitive to the agonist because not internalized 
but recycled to the plasma membrane. 
 
In support to these observations in primary cells and at IHC, we have 
performed drug experiments in H295R cells after silencing NEFM. 
NEFM knockout attenuates dopamine-induced inhibition on aldosterone 
secretion, and amplifies both stimulatory and inhibitory effects on aldosterone 
secretion of D1R agonist and antagonist, respectively, thus suggesting a 
direct D1R/NEFM interaction.  This was confirmed by co-immunoprecipitation. 
 
Of note, Immunofluorescence staining for D1R in H295R cells after shRNA 
transfection showed that NEFM knock-down increased D1R localization at 
plasma membrane. In untransfected cells, the red staining was mainly 
cytoplasmic. 
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Interestingly, NEFM is up regulated in H295R cells treated with D1R agonist 
fenoldopam, thus supporting the evidence that it is involved in agonist-
induced D1R desensitisation. 
D2R signalling was not affected by NEFM knock-out, as aldosterone 
stimulation by its antagonist metoclopramide did not differ from controls.   
 
We concluded that NEFM is involved in regulating aldosterone inhibition by 
dopamine, since it internalizes the adenyl-cyclase (AC) stimulating dopamine 
D1R.   
The high NEFM levels in ZG could explain why D1R binding sites were not 
detectable in human adrenal as observed by others. 
 
The disappearance of NEFM protein not only in H295R cells but especially in 
primary, ZG-like, APA cells transfected with mutant KCNJ5 suggests that 
KCNJ5 genotype is directly correlated to the down-regulation of NEFM in 
common ZF-like APAs. 
This observation could suggest that even though ZF-like APAs share 
phenotypical features with normal cortisol-producing ZF, they are likely to 
arise from ZG cells with mutant KCNJ5. 
 
NEFM and other genes encoding for NF subunits are methylated in several 
types of cancers and we could speculate that NEFM is downregulated in ZF 
and ZF-like APAs and in KCNJ5 transfected cells through this epigenetic 
mechanism, but we did not investigate it experimentally (Calmon et al., 2015; 
Shen et al., 2016).  
 
As mentioned before, CYP11B2 positive cell clusters (APCCs) carry 
mutations in ATP1A1 and CACNA1D but not in KCNJ5 gene, even though the 
latter are the most common in sporadic APAs.  
NEFM staining was diffuse all over ZG and did not present a patchy pattern 
as CYP11B2, thus suggesting that NEFM is not a marker of APCC, nor co-
localized with CYP11B2, but can rather be considered a marker of normal or 
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adenomatous ZG cells, and its disappearance a signature of KCNJ5 mutant, 
ZF-like, APAs arising from ZG. 
 
Although this study presents a within-patient comparison of ZG, ZF, and APA 
transcriptomes, its design leaves some limitations. One is that this study for 
obvious ethical reasons does not include completely normal adrenals but 
reflects current indications for adrenalectomy in our hospital. 
Secondly, the immortalised adrenal cell line, H295R, is not a perfect model for 
native ZG cells. These results support our current hypothesis that the human 
ZG highly expresses genes, which inhibit rather than stimulate aldosterone 
secretion and cell proliferation.   
 
Because the primary focus of our investigation was NEFM, we have 
concentrated on the D1R, in whose regulation NEFM was previously 
implicated. The D2R function and expression in normal ZG and APAs and its 
correlation with the cellular composition relies mainly on previous literature. 
Our experiment using metoclopramide showed that D2R blockade unmasks a 
net stimulatory effect of dopamine on aldosterone secretion, but future studies 
on the relationship between APA genotype and D2R function may be 
required. We used immunostaining rather than autoradiography, to show 
probable surface expression of D1R in ZF-like APAs and NEFM- silenced 
adrenocortical cells.  However, D1R agonist and antagonist modulated 
aldosterone secretion in H295R cells and, more importantly, in primary cells 
from APAs, suggested that they express functional receptors. 
 
 
In conclusion, we confirmed the ZG selective expression of NEFM. Functional 
analysis of NEFM in H295R cells supports NEFM role in adrenal 
steroidogenesis, and although NEFM was a “ZG gene” it inhibited aldosterone 
production. 
This suggests that “ZG-specific” genes may be more involved with cell 
machinery that inhibits rather than stimulates hormone secretion.  
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We also found that NEFM plays a role in dopamine inhibition of aldosterone 
since it prevents dopamine activation of aldosterone secretagogue signalling 
by D1R. 
This is evident in both normal ZG and in ZG-like APAs. In ZF-like, mutant 
APA, D1R is membranous and primary cells from this APA subtype secrete 
significantly more aldosterone in response to D1R agonist.   
Disappearance of NEFM in KCNJ5 mutant cells could suggest that ZF-like 
APAs may originate from ZG cells rather than ZF-cells. 
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Chapter 4. Role of an anoctamin family member, ANO4, in human 
adrenal cells 
4.1 Abstract 
Somatic mutations in ATP1A1 and CACNA1D genes are more common in 
small, ZG-like APAs, whereas KCNJ5 mutations are more frequently found in 
larger ZF-like tumours.  These two subtypes differ also in terms of gene 
expression profile, thus raising the question about the cell origin of APAs and 
the possible existence of ZG markers.  To answer this question, we have 
performed a microarray analysis comparing the transcriptome of adjacent ZG 
and ZF and tumour (T) of 14 APA and 7 phaeochromocytoma patients.  We 
found that 28 genes were at least 5-fold over-expressed in ZG vs ZF. 
The third most ZG-selective gene was ANO4, a member of the anoctamin 
family that also includes Ca2+-activated chloride channels (CaCCs).  
Immunohistochemistry confirmed ZG-selective expression of ANO4 protein. 
The staining pattern was prevalently cytoplasmic and was also confirmed at 
immunofluorescence in transfected HEK293 and H295R cells.  
 ANO4 overexpression in H295R cells increased aldosterone secretion and 
CYP11B2 mRNA expression, and in the presence of Ionomycin or AngII, 
aldosterone production was reduced in comparison to controls. 
Yellow fluorescent protein assay was performed to investigate ANO4 activity 
as a CaCC in comparison with other anoctamins in HEK293 cell and found 
that when exposed to calcium ionophores, ANO4 generated only small 
chloride currents.  
In conclusion ANO4 is one of the most highly expressed genes in ZG vs ZF. 
When overexpressed in an in vitro model of hyperaldosteronism and in 
presences of calcium agonists and aldosterone secretagogues, it negatively 
regulates aldosterone synthesis and secretion.  Although belonging to a family 
of CaCCs, it does not generate significant chloride currents.  
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4.2 Introduction 
Chloride (Cl-) channel family regulates both physiological housekeeping 
functions such as pH and cell volume regulation, and more specialized 
physiological functions such as transepithelial electrolyte/fluid transport in 
epithelia, contraction and excitability.  These functions are maintained by 
various types of Cl- channels, generally classified in four groups according to 
the mechanisms of activation: cAMP-regulated chloride channels, ligand-
gated chloride channels, voltage-activated chloride channels, and calcium-
activated chloride channels (CaCCs). 
Three different laboratories have identified the first gene encoding for a CaCC 
in 2008 (Caputo et al. 2008; Schroeder et al. 2008; Yang et al. 2008), about 
thirty years after the first description of these currents.  
Two genes definitely encoding CaCCs, ANO1 and ANO2, belong to a family 
that includes eight more genes (ANO1-10).  All the members share a common 
unique structure, eight trans-membrane segments while both N- and C- 
termini extending in the cytoplasm.  The putative trans-membrane domains 
are highly conserved, while the sequences identity is more divergent in other 
regions (20–60%).  
ANO1 and ANO2 protein sequences are closer than the other members, more 
evolutionary distant. ANO1 is widely expressed in secretory epithelia, smooth 
muscle cells and other tissues, poorly expressed in the nervous system.  In 
contrast, ANO2 is exclusively expressed in neurons (Pifferi et al. 2009; Stöhr 
et al. 2009).  The functional meaning of this differential expression relies in 
their different [Ca2+]i sensitivity (∼10-fold lower in ANO2 vs ANO1).)  While 
ANO1 seems to be constitutively open in epithelial cells with continuous 
transport activity, ANO2 could be specifically tailored for transient and rapid 
signals with [Ca2+]i peaks and spikes which are more relevant in neurons. 
4.2.1 ANO1  
The prototype of anoctamins is the widely expressed ANO1, which was 
reported as CaCC in 2008.  When heterologously expressed, it behaves as a 
CaCC, showing the typical electrophysiological properties: it preferentially 
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permeates large anions, its voltage/current relationship is dependent on 
[Ca2+]i concentration as at low concentrations, it is characterized by reversible 
voltage-dependent activation and time-dependent outward rectification.  
ANO1-mediated currents are activated by any physiological or experimental 
increase of [Ca2+]i. 
Alternative splicing in different tissues and organs generates different 
isoforms of ANO1 and is responsible for the different electrophysiological 
properties of CaCCs in different cell types.   
 
ANO1 is expressed robustly in vascular smooth muscle cells, and knockout 
mice for ANO1 show a cystic fibrosis phenotype with impaired muco-ciliary 
clearance and accumulation of mucus in the airways, tracheomalacia and 
collapsed airways (Rock et al. 2008; Rock & Harfe 2008).  
 
ANO1 plays a role in arteriolar and capillary blood flow and can play a role in 
the cardiovascular system too as mice lacking vascular ANO1 had lower 
systemic blood pressure and a decreased hypertensive response following 
vasoconstrictor stimuli (Heinze et al. 2014). 
 
ANO1 is also up regulated in some tumours like gastrointestinal stromal 
cancers, oral and neck carcinoma. In vitro, overexpression of ANO1 
stimulates cell movement, while pharmacological blocking or silencing of 
ANO1 decreases cell migration (Ayoub et al. 2010). 
 
So far, there is no convincing evidence that anoctamins other than ANO1 and 
ANO2 behave as ion channels.   
Recent studies gave contrasting results.  Only one demonstrated that, in 
principle, all examined anoctamins are able to generate CaCCs, when 
overexpressed and activated through the P2Y2 purinergic receptor or with 
ionomycin which increases [Ca2+]i, although less quickly activated than ANO1 
(Y Tian et al. 2012).   
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On the other hand, more than one study showed that expression of ANO3-7 in 
HEK293 cells did not generate currents.  In particular, one of these showed 
that only ANO1 and ANO2 traffic to the plasma membrane when expressed 
heterologously, while the other intracellular anoctamins may rather localise to 
the endoplasmic reticulum, the poor cell membrane trafficking and subcellular 
localisation being responsible of the absence of currents (Duran et al. 2012).  
 
The different results from these experiments could be due to the use of 
different cell lines as expression models or to different ways of causing 
activation of Ca2+ signalling.  It is also possible that anoctamins need 
heterodimerization with other paralogues to work as a CaCC, thus single gene 
overexpression gave negative results. 
4.2.2 ANO6 
ANO6 recently came to attention as it has been found to be defective in 
patients suffering from a rare bleeding disorder, the Scott syndrome. 
As an ion channel, ANO6 has been described mainly as an outwardly 
rectifying, Ca2+-dependent and volume regulated Cl- channel, but also as a 
Ca2+ regulated non-selective cation channel permeable to Ca2+ and Na+.  
Beside these ion channel properties, it is pathophysiological relevant as it was 
found to play a central role in Ca2+-mediated scrambling of membrane 
phospholipids (PS), and in cell blebbing.   
 
ANO6 has been identified as a scramblase (Suzuki et al. 2010), and missense 
mutations had been identified in patients with a rare congenital defect in 
coagulation named Scott syndrome.  Their bleeding phenotype is due to an 
impaired scrambling activity of PS in platelets, as the lack of pro-coagulant 
phosphatidylserine expose in response to increases of [Ca2+]i prevents the 
activation of coagulation factors.  
The two leaflets of the plasma membrane of quiescent cells have an 
asymmetric composition in PS, mainly sphingomyelin and phosphatidylcholine 
in the outer layer, phosphatidylserine and phosphatidylethanolamine in the 
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inner one.  Once established, the PS distribution is not easily disrupted.  
Flippases maintain the asymmetry of the plasma membrane in an ATP-
dependent manner, scramblases mediate Ca2+-dependent but ATP 
independent movement of all PS in both directions.  The asymmetry is lost 
during physiological functions such as platelets activation and apoptosis. 
 
It is still unclear how the scramblase activity of ANO6 could be related to its 
ion channel properties.  Martins et al. found that whole-cell currents mediated 
by ANO6, as outwardly rectifying chloride channel (ORCC), are only activated 
by massive increases of [Ca2+]i induced by ionomycin, and by apoptotic 
stimuli (Martins et al. 2011). 
On the other hand, activation of the intrinsic or mitochondrial apoptosis with 
minimal or no increases of [Ca2+]i stimulated scrambling of PS without 
generating Cl- currents.  Pharmacological interventions such as inhibitors of 
Cl- channels do not affect PS scrambling activity, while they do on ANO6 
CaCC activity.  These currents were not observed in Scott patients’ 
lymphocytes, either exposed to Fas ligand or to Ca2+ionophores.   
 
Taken together, these observations support not only the hypothesis of two 
different pathways for PS exposure, one dependent and one independent 
from Ca2+, but also the speculation that the ANO6 activities as a CaCC and as 
scramblase are not related. 
At least two studies showed that ANO6 could generate cation currents 
alongside Cl− currents (Grubb et al. 2013; Kmit et al. 2013).  These currents 
(described as nonselective cation currents, as conducted both Na+ and Ca2+) 
were clearly present in wild type lymphocytes, but absent in lymphocytes from 
Scott patients.  Similarly, ANO1 was described to change its anion 
permeability with increasing Ca2+ concentrations (Tian et al. 2012). 
 
It was proposed that ANO6 mediates also Ca2+ influx required to increase 
[Ca2+]i  as,  when heterologously expressed, its currents showed prominent 
outward rectification even at high [Ca2+]i, unlike CaCCs  which are typically 
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characterized by a linear current-voltage (I-V) relationship at saturating [Ca2+]i  
thus suggesting that ANO6 does not behave as a CaCC.  Moreover, it was 
permeable to divalent cations,  but rather as small-conductance Ca2+-
activated nonselective cation channel more permeable to Ca2+ than 
monovalent cations, with synergistic gating by Ca2+ and voltage (Yang et al. 
2012). 
4.2.3 Scramblase activity of other anoctamins 
In this scenario of contrasting evidences, Suzuki et al. analysed scrambling 
and ion channel activities of all anoctamins by expressing them in a mouse 
lymphocyte cell line with an inactivated allele in the ANO6 gene.  They found 
that ANO6, but also ANO3, 4, 7, and 9 behave as scramblases, but with 
different preference to lipid substrates.  
ANO6 and ANO4 are the paralogues with the stronger ability to enhance the 
PS exposure in comparison to ANO7 or ANO10.  Cells expressing ANO4 
have a stronger scramblase activity than ANO6, as they constitutively 
internalized marked phosphatydicoline a gal-Ceramide (as endogenous levels 
of Ca2+ are sufficient to activate it), and this internalization was strongly 
enhanced after exposure to ionomycin.  No or very weak PS exposure was 
found in cells expressing ANO1, ANO2, ANO3, ANO5, ANO8, and ANO9.  
The authors also showed that at patch clamp analysis in 293T cells ANO1 
and ANO2, but not other family members, generate currents as CaCC. 
These results suggested that ANO3, 4, 6, 7, and 10 scramble various 
phospholipids and glycosphingolipids with some different substrate preference 
(Suzuki et al. 2013). 
 4.2.4 Chloride channels in the adrenal gland 
Chorvatova et al. described a Ras-dependent transient chloride current 
activated by ACTH at very low concentrations in bovine ZG cells through 
activation of Ras by beta gamma subunits.  These currents can have a 
functional role in aldosterone production at physiological ACTH 
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concentrations where cAMP production is very low (Chorvatova et al. 1998; 
Chorvátová et al. 2000). 
This was the only study describing a Cl- current in the ZG cell.  No significant 
Cl- currents were detected in early studies.  Spat et al. examined Cl- currents 
with the patch-clamp technique in rat ZG cells.  With the application of nearly 
symmetrical Cl- concentration, and after inhibiting K+ currents, they did not 
find any significant channel activity.  However, in a significant fraction of the 
cells, the slow activation of a tiny inward current could be observed at strongly 
negative voltages.  This was significantly accentuated by reducing 
extracellular pH.  Both the kinetic and pharmacological characteristics of this 
inwardly rectifying current suggest that it passes through ClC-2Cl channels 
(Spät & Hunyady 2004; Chorvatova et al. 1999). 
In synthesis, the functional meaning of Cl- currents in adrenal cells is still to be 
determined. Up to now, none of the described channels are CaCCs. 
4.2.5 ANO4: previous literature  
Controversial data have been published about ANO3–10 members. Duran et 
al. described that ANO3-7 as intracellular proteins which did not conduct 
Ca2+-activated Cl- currents (Duran et al. 2012). 
On the other hand, another group have previously showed that most 
anoctamins overexpressed in the same cell line, HEK293, were expressed on 
cell membrane (Schreiber et al. 2010). 
 
In particular for ANO4, it has previously been reported that, when co-
expressed with purinergic receptor P2Y2, it can conduct currents of variable 
magnitudes activated by ATP or by ionomycin. Stimulation of purinergic 
receptors, through an increase of [Ca2+]i, depolarized membrane voltages in 
all anoctamins transfected cells except ANO4, which hyperpolarized the cells. 
Overexpressed in HEK293, ANO4 localized at plasma membrane level (Y 
Tian et al. 2012). 
 
ANO4 shares about 40.7% identity with the scramblase ANO6. Suzuki et al 
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showed that ANO4 constitutively behaves as a scramblase, and its activity is 
even stronger than ANO6 with specific affinity for some phospholipids.  No 
CaCC activity was found when they measured whole cell current in 
transfected HEK293 cells.   
Duran et al. found the same result in the same cell system, where ANO4 does 
not localise on the plasma membrane, but its localisation is intracellular.  This 
subcellular distribution of ANO4 is consistent with the lack of finding of 
chloride currents (Suzuki et al. 2013; Duran et al. 2012). 
4.3 Methods and Study design 
In order to investigate the role of ANO4 in the adrenal, we have characterized 
its protein expression in human adrenals.  We also investigated the function of 
ANO4 on adrenal steroidogenesis and its effect on the cell proliferation.  
Chloride currents were measures at YFP assay.    
4.3.1 Expression plasmids  
P-receiver M29 containing N terminus eGFP-tagged human ANO4 (encoding 
955 amino acids) was purchased from Genecopoeia and shared with Dr Louis 
Galietta, Gaslini Institute Genoa, Italy.  
P-receiver M29 vector control plasmid was generated from this plasmid. The 
DACH1 (706aa) plasmid was first digested by the restriction enzymes BamHI 
and HindIII (New England BioLabs Inc, UK) according to the manufacturer’s 
instructions to remove ANO4 sequence. Then the DNA fragments left were 
blunted by DNA polymerase I, Large (Klenow) Fragment (New England 
BioLabs Inc, UK) to remove the 3’ overhangs. After blunting, the products 
were purified by electrophoresis and DNA purification kit (Wizard® SV Gel 
and PCR Clean-Up System, Promega, USA). Finally, the purified products 
were ligated together by T4 DNA ligase (New England BioLabs Inc, UK) 
according to the manufacturer’s instructions.  
The plasmids were transformed into One Shot® TOP10 Chemically 
Competent E. coli (Invitrogen, USA) according to the manufacturer’s 
instructions and maxiprepped using EndoFree Plasmid Kits (Qiagen, UK) as 
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described in Chapter 1. All the above plasmids were sequenced at the end of 
each step to make sure their sequences were correct. 
4.3.3 Transient transfections  
For small interfering RNA (siRNA) experiments, H295R cells were seeded at 
1.0×105/well in 24-well plates in antibiotic-free complete culture medium. After 
12 hours the medium was replaced by 500 µl of transfection medium with a 
final concentration of 50 nM of On-target plus human ANO4 siRNA-smart pool 
or On-target plus human non-targeting siRNA (Dharmacon, USA). The cells 
were then incubated at 37°C in 5% CO2 for 48 h, then the supernatant was 
harvested for aldosterone measurement and the cells were harvested for 
mRNA expression and protein assay.  
 
For over-expression experiments, H295R cells were seeded at 1.0×105/well in 
24-well plates in antibiotic-free complete culture medium. After 12 hours the 
medium was replaced by 500 µl of nil media to starve the cells.  After at least 
6 hours, the transfection was carried out according to the manufacturer 
instructions for Lipofectamine 3000. The ratio of Lipofectamine 3000 to 
plasmid was 2:1 per well. Before transfection, the mixture was incubated at 
room temperature for 15 min.   After incubation for 48 h at 37°C in 5% CO2, 
cells were harvested for analysis of mRNA expression and protein assay 
while the supernatant were harvested for aldosterone measurement. 
Transfection efficiency was monitored by immunofluorescence.  
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Figure 4.1: schematic representation of the plasmid used for ANO4 over-
expression (From the Genecopoeia website). 
 
4.3.4 CaCC currents measurement by YFP assay 
YFP assay is a cell-based assay with an engineered halide-sensitive molecule 
yellow fluorescent protein originally developed by Galietta and Verkman 
(Galietta et al. 2001). 
 
This assay detects the iodide (I-) influx. Cells expressing HS-YFP and CaCCs 
are exposed to I--rich solution and a Calcium agonist such as ionomycin at 
different concentrations. The resulting I- influx conducted by CaCCs causes a 
rapid quenching of HS-YFP fluorescence. Hence, the rate of fluorescence 
quenching is proportional to CaCC activity (Figure 4.2). 
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Figure 4.2: Influx detection with the halide-sensitive yellow fluorescent 
protein (HS-YFP). Cells expressing HS-YFP and CaCCs are exposed to a 
solution with high I- concentration and a Ca2+ agonist. The resulting I- 
influx through CaCCs causes a rapid quenching of HS-YFP 
fluorescence. The rate of fluorescence quenching is proportional to 
CaCC activity (modified from Pedemonte &Galietta 2014). 
 
 
 
 
HEK-293 cells were seeded in 96-well microplates (25,000 cells/well) in 
100 µl of antibiotic-free culture medium. After 6 h, cells were co-transfected 
with plasmids carrying the coding sequence for anoctamin constructs and the 
YFP.  After 24 h, the fresh culture medium plus antibiotics replaced 
transfection media. The HS-YFP functional assay was performed 48 h after 
transfection.  Cells were washed two times with PBS and incubated for 30 min 
with 60 µl of PBS. After incubation cells were transferred to a microplate’s 
reader (FluoStar Galaxy; BMG Labtech, Ortenberg, Germany) for CaCC 
activity determination. The plate reader was equipped with high-quality 
excitation (ET500/20 ×) and emission (ET535/30 m) filters for YFP (Chroma 
Technology Corp., Brattleboro, VT, USA). Each assay consisted of a 
continuous 14 s fluorescence reading with 2 s before and 12 s after injection 
of 165 µl of modified PBS (Cl− replaced by l− with final concentration 100 mM) 
also containing 1 or 10 µM ionomycin.  Data were normalized to the initial, 
background-subtracted, fluorescence. To determine fluorescence quenching 
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rate (QR) associated with l− influx, the final 11 s of the data for each well were 
fitted with an exponential function to extrapolate the initial slope (dF/dt). 
 
 
4.3.5 XTT assay 
 
XTT is a new tetrazolium dye used in apoptosis, cell proliferation and 
cytotoxicity tests. XTT is a colourless compound: its reduction causes the 
breaking apart the positively charged quaternary tetrazole ring and the 
generation of a soluble, bright orange coloured formazan derivative.  
The usage of an intermediate electron carrier, PMS (N-methyl 
dibenzopyrazine methyl sulphate), as activation reagent increases the 
sensitivity of the assay as it drives XTT reduction and formation of its 
derivative. XTT dye reduction occurs at the cell surface. PMS mediates 
electrons transfer at the cell surface from the mitochondrial oxidoreductases. 
In brief, the cells were grown in a 96-well plate at a density of 105 cells/well in 
100 µL of culture medium and transfected with Lipofectamine.  After 48 hours 
from transfection the assay was performed: 25 µL of XTT/PMS solution were 
added directly to each well containing 100 µL cell culture. The solution was 
made as described: 4 mg of XTT were dissolved in 4 mL of warm culture 
media.  10 µL of the PMS solution (10 mM PMS solution in PBS) were added 
to the 4 mL.  
Cells were incubated for 2 hours at 37°C in a CO2 incubator.  The plate was 
read at 450 nm in a plate reader. 
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Figure 4.3: The Colorimetric Reduction of XTT by Cellular Enzymes 
(from XTT Cell Proliferation Assay Kit ATCC instruction manual). 
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4.4 Results 
 
4.4.1 Microarray  
Microarray comparison of ZG vs ZF from 21 human adrenals found that ANO4 
was the third most up-regulated gene (19.9-fold higher, P=6.6x10-24, Figure 
4.4). ANO4 expression in most APAs was almost as low as in ZF, regardless 
of genotype. 
 
 
 
 
 
Figure 4.4: Figure 3.1: Representative RMA values of ANO4 
automatically clustered ZF, ZG and APA separately.  RMA: Robust 
Multichip Average. T: Tumor (Aldosterone-Producing Adenoma). ZF: 
Zona Fasciculata. ZG: Zona Glomerulosa. Group legend: FM: ZF-Mutant 
KCNJ5. FP: ZF-Phaeocromocytoma. FW: ZF- wild-type KCNJ5. GM: ZG-
Mutant KCNJ5. GP: ZG-Phaeocromocytoma. GW: ZG-KCNJ5 wild-type. 
TM: Tumor -mutant KCNJ5. TW: Tumor- Wild-type KCNJ5. 
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The microarray results were validated and confirmed by qPCR performed on 
LCM samples (Figure 4.5). 
 
 
 
 
 
 
 
 
Figure 4.5: ANO4 qPCR validation of microarray findings performed on 
LCM samples from ZG, ZF and APAs of 7 patients with 
phaeocromocytoma, 7 patients with KCNJ5 mutant, and 7 patients with 
KCNJ5 wild-type APAs. Results are expressed as Mean and S.E.M of 2^-
dCT. ZF: Zona Fasciculata. ZG: Zona Glomerulosa. T: Tumor 
(Aldosterone-Producing Adenoma). Multiple t-tests were applied. 
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4.4.2 ANO4 protein expression in AAG and APAs 
ANO4 protein was selectively expressed in the ZG of adjacent adrenal glands 
(AAG) next to an APA or AAG next to a Phaeocromocytoma (Figure 4.7).  In 
the positive control sections (human kidney sections), ANO4 stain was 
observed in the renal tubules and fainter in the glomeruli (Figure 4.6).  In the 
adrenal ZG the staining was cytoplasmic. 
 
 
 
 
 
 
 
 
Figure 4.6: IHC of ANO4 in human kidney sections.  The staining was 
mainly tubular and less intense in glomeruli. 
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Figure 4.7: IHC of ANO4 in the normal adrenal cortex adjacent to a 
phaeocromocytoma. The staining was selective for ZG and appeared to 
be mainly cytoplasmic (C=capsule). 
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4.4.3 ANO4 protein expression in H295R and HEK293 cells: 
Immunofluorescent staining in transfected cells 
We evaluated ANO4 protein expression pattern in transfected H295R and 
HEK293 cells by confocal microscopy.  We have used two plasmids with 
different tags as probes, N-terminus eGFP for H295R and C-3xHA-tag for 
HEK293 cells.  The experiments were performed independently in Genoa (for 
HEK293 cells) and Cambridge (H295R cells). 
 
The cells were counter stained with nuclear staining DAPI and, in case of 
H295R cells, plasma membrane marker WGA.  
In both HEK293T and H295R cells and independently from the tag, the 
staining for ANO4 in both the cell lines was cytoplasmic (Figure 4.8 and 4.9). 
However the caveat for these experiments is that ANO4 has been 
overexpressed and its protein products includes tags. 
 
 
 
 
Figure 4.8: Immunofluorescent detection of ANO4 in transfected HEK293 
cells. Blue staining corresponds to nuclei, green fluorescence to ANO4. 
Red staining corresponds to the HA-tag of transfected ANO4.  Merge 
images show cytoplasmic localisation of ANO4 (Courtesy of Dr Paolo 
Scudery, Genoa). 
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Figure 4.9: Confocal microscopic images of immunofluorescent staining 
showed transfected ANO4 staining (green-GFP), plasma membrane (red-
WGA), nuclei (blue-DAPI) and the overlay of them in the same sight field 
in H295R cells.  ANO4 staining is mainly cytoplasmic. Pictures are 
representative of three fields.  
 
 
 
  
 
 
 
 
139 
4.4.4 Effects of ANO4 overexpression in H295R cells 
To evaluate the effects of ANO4 on aldosterone production, we transfected 
the adrenocortical cell line H295R with a plasmid expressing N-terminus 
eGFP tagged ANO4 and used Lipofectamine 3000 according to the 
manufacturer’s instruction.  The cells were harvested at 48 hours from 
transfection for RNA extraction or protein concentration measurement and 
media collected for HTRF aldosterone assay. 
 
 
Comparing to controls, ANO4 mRNA increased by 12.6 fold in transfected 
cells (N=12, P< 0.0013; Figure 4.10).  This change resulted in a significant 4.3 
fold increase in CYP11B2 mRNA (N=12, P<0.05, Figure 4.11). 
 
 
Similarly, ANO4 overexpression stimulated aldosterone synthase transcription 
factor NR4A2.  Comparing to control vector, overexpression of ANO4 
significantly stimulated NR4A2 mRNA expression by 2.4 fold (N=12, P<0.05, 
Figure 4.12). 
 
 
However, aldosterone changes induced by ANO4 overexpression were not 
significant, although a trend to aldosterone increase was observed (N=12, ns, 
Figure 4.13). 
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Figure 4.10: Effect of ANO4 overexpression on ANO4 mRNA in H295R 
cells.  At 48 hours from transfection ANO4 mRNA expression increased 
by 12 fold, comparing to empty vector (EV) (*P=0.001). Data are shown in 
geometric mean values + S.E.M. Results are expressed as geometric 
mean values with SEM and compared using the 2-sided Student t test. 
The significance level of P<0.05 was considered to indicate statistical 
significance. 
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Figure 4.11: Effect of ANO4 overexpression on CYP11B2 mRNA in 
H295R cells.  At 48 hours from transfection CYP11B2 mRNA expression 
increased by 4.4 fold, comparing to empty vector (EV) (*P<0.05). Results 
are expressed as geometric mean values with SEM and compared using 
the 2-sided Student t test. The significance level of P<0.05 was 
considered to indicate statistical significance. 
 
 
VE ANO4
0
2
4
6
C
YP
11
B
2 
FC
* * P<0.05
EV 
  
142 
142 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12:  Effect of ANO4 overexpression on NR4A2 mRNA in H295R 
cells. At 48 hours from transfection CYP11B2 mRNA expression 
increased by 2.4 fold, comparing to empty vector (EV) (*P<0.05). Results 
are expressed as geometric mean values with SEM and compared using 
the 2-sided Student t test. The significance level of P<0.05 was 
considered to indicate statistical significance. 
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Figure 4.13: Aldosterone secretion in response to the overexpression of 
ANO4 in H295R cells. There was a trend toward a stimulation of basal 
aldosterone secretion but it was statistically non-significant. Results are 
expressed as mean values with SEM and compared using the 2-sided 
Student t test. The significance level of P<0.05 was considered to 
indicate statistical significance. 
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4.4.5 Effects of ANO4 silencing in H295R cells 
 
Silencing ANO4 significantly reduced its protein levels at 48 hours (Figure 
4.14). 
 
 
 
 
Figure 4.14: Western blot figures showing ANO4 and GAPDH control in 
H295R cells at 48 hours from silencing ANO4. 
 
 
Silencing ANO4 for 48 hours affected CYP11B2 and NR4A2 mRNA 
expression levels, without changing aldosterone secretion. 
 
Silencing ANO4 for 48 hours induced 37% down-regulation of CYP11B2 
mRNA (N=6, P<0.05, Figure 4.15) and a 35% down-regulation of NR4A2 
mRNA (N=6, P<0.05, Figure 4.16).   
 
Similar to overexpression, silencing ANO4 did not significantly affect 
aldosterone secretion although a trend to reduction was observed (N=6, ns, 
Figure 4.17). 
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Figure 4.15: Effect of silencing ANO4 on CYP11B2 mRNA in H295R cells. 
At 48 hours from silencing CYP11B2 mRNA expression decreased by 
37%, comparing to non-targeting (*P<0.05). Results are expressed as 
geometric mean values with SEM and compared using the 2-sided 
Student t test. The significance level of P<0.05 was considered to 
indicate statistical significance. 
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Figure 4.16: Effect of silencing ANO4 on NR4A2 mRNA in H295R cells. 
At 48 hours from silencing NR4A2 mRNA expression decreased by 35%, 
comparing to non-targeting (*P<0.05). Results are expressed as 
geometric mean values with SEM and compared using the 2-sided 
Student t test. The significance level of P<0.05 was considered to 
indicate statistical significance. 
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Figure 4.17: Aldosterone secretion in response to ANO4 silencing in 
H295R cells. There was a trend toward a downregulation of basal 
aldosterone secretion but it was statistically non-significant.  Results 
are expressed as mean values with SEM and compared using the 2-
sided Student t test. The significance level of P<0.05 was considered to 
indicate statistical significance. 
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4.4.6 Effect of ANO4 on stimulated aldosterone secretion 
As ANO4 overexpression or silencing did not affect basal aldosterone 
secretion in H295R cells, we measured aldosterone response to 
secretagogues in transfected cells. 
 
Among all aldosterone secretagogues we have chosen Ang II, Ionomycin and 
ATP as they increase intracellular calcium concentration, the trigger to 
activate CaCCs, via different pathways. 
 
The experiment design was similar to the transfection described so far, 
although at 36 hours we have replaced the media with starving medium for six 
hours and then treated the cells with different drugs (AngII at 10-8 M, 
Ionomycin 1 µM and ATP 10-6M) for 24 hours. Aldosterone was measured by 
HTRF assay and normalized by protein concentration measures by BCA 
assay. 
 
 
After stimulation with AngII (10-8 M for 24 hours), aldosterone secretion 
increased by 3.5 fold in controls, whereas the increase in ANO4 transfected 
cells was smaller, 2.25 fold in comparison to basal concentration (N=6, 
P<0.05, Figure 4.18). 
 
 
In a similar experiment, the cells were treated with Ionomycin (1 µM for 24 
hours).  Ionomycin is a calcium ionophore that increases intracellular calcium 
concentration by stimulating its release from the endoplasmic reticulum 
storages.  Calcium signalling is a known stimulator of aldosterone secretion. 
 
 
Ionomycin, increased aldosterone by 2.7-fold in controls, whereas in ANO4 
transfected cells the increase was significantly smaller, 1.2-fold (N=6, P<0.05, 
Figure 4.19). 
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Figure 4.18: Effect of ANO4 overexpression in H295R on AngII 
stimulated aldosterone secretion. Aldosterone secretion increased by 4 
fold (vs basal aldosterone) in controls, and only 2.25 fold in ANO4 
transfected cells (*P<0.05). Results are expressed as geometric mean 
values with SEM and compared using one-way ANOVA. The significance 
level of P<0.05 was considered to indicate statistical significance. 
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Figure 4.19: Effect of ANO4 overexpression in H295R on Ionomycin 
stimulated aldosterone secretion. Aldosterone secretion increased by 
2.7 fold (vs basal aldosterone) in controls, and only 1.2 fold in ANO4 
transfected cells (* P<0.05). Results are expressed as geometric mean 
values with SEM and compared using one-way ANOVA. The significance 
level of P<0.05 was considered to indicate statistical significance. 
 
 
Another calcium agonist was tested.  Nucleotide ATP is known to activate 
purinergic signalling via P2Y receptors and activates calcium signalling in 
H295R cells (Nishi et al. 2013). 
 
ATP treatment for 24 hours increased aldosterone secretion by 1.5 fold in 
controls but did not affect aldosterone secretion in ANO4 transfected cells 
(N=6, P<0.05, Figure 4.20). 
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Figure 4.20: Effect of ANO4 overexpression in H295R on ATP stimulated 
aldosterone secretion.  ATP increased aldosterone secretion by 1.5 fold 
(vs basal aldosterone) in controls, and reduced it by 0.25 fold in ANO4 
transfected cells (*P<0.05). Results are expressed as geometric mean 
values with SEM and compared using one-way ANOVA. The significance 
level of P<0.05 was considered to indicate statistical significance. 
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4.4.7 Comparison with other anoctamins 
We compared the effects of ANO4 overexpression in H295R cells with those 
of two other anoctamin family members, ANO1 and ANO6: the former is a 
plasma membrane protein with Ca2+-dependent Cl− channel function, the 
latter has been reported as a scramblase (Caputo et al. 2008; Suzuki et al. 
2010).   
 
The outcome was basal and stimulated aldosterone secretion and cell 
proliferation.  We have also evaluated the effects of different anoctamins on 
iodide currents as evaluated at YFP assay, and compared those generated by 
ANO4, ANO1 and ANO2, two CaCCs with different sensitivity to [Ca2+]I and an 
intracellular anoctamin, ANO5.  The latter was chosen mainly for its 
expression pattern, as ANO4 is expressed as an intracellular protein in 
human adrenal cells and in H295R and HEK293 cell lines.  
 
4.4.7.1 Aldosterone secretion and synthesis  
We evaluated aldosterone secretion and CYP11B2 mRNA expression in 
basal or stimulated conditions (with AngII 10-8M for 24 hours) in H295R 
transfected with empty vector (EV), ANO1, ANO4 or ANO6.   
 
We found that, compared to basal aldosterone in controls, basal 
aldosterone secretion was 2 fold higher, 1.3 fold and 1.1 higher in ANO1, 
ANO4 and ANO6 transfected cells, respectively.  Aldosterone response to 
AngII was 2.6, 3.7, 2.2 and 2.7 fold higher in comparison to basal controls 
in EV, ANO1, ANO4 and ANO6 transfected cell, respectively.  No significant 
differences were found in both conditions between the three anoctamins 
(N=6, ns, Figure 4.21). 
 
CYP11B2 mRNA in basal conditions was 2, 2.7 and 2 fold higher in ANO1, 
ANO4 and ANO6, respectively.  CYP11B2 mRNA expression in response to 
AngII was 14.6, 20.7, 37.7 and 18.9 fold higher in comparison to basal 
controls in EV, ANO1, ANO4 and ANO6 transfected cell, respectively.  Ang 
  
153 
153 
II stimulated CYP11B2 mRNA expression was significantly higher in ANO1 
and ANO4 vs stimulated VE (N=6, P<0.05, Figure 4.22). 
 
 
 
 
 
 
 
Figure 4.21: Effect of ANO1, ANO4 and ANO6 overexpression in H295R 
on AngII stimulated aldosterone secretion. Aldosterone secretion 
increased by 2.6, 3.7, 2.2 and 2.7 fold higher in comparison to basal 
controls in EV, ANO1, ANO4 and ANO6 transfected cell, respectively.  
No significant differences were found in both conditions between the 
three anoctamins. 
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Figure 4.22: Effect of ANO1, ANO4 and ANO6 overexpression in H295R 
on AngII stimulated CYP11B2 mRNA expression. CYP11B2 mRNA in 
basal conditions was 2, 2.7 and 2 fold higher vs controls in ANO1, 
ANO4 and ANO6, respectively.  CYP11B2 mRNA expression in 
response to AngII was 14.6, 20.7, 37.7 and 18.9 fold higher in 
comparison to basal controls in EV, ANO1, ANO4 and ANO6 
transfected cell, respectively.  Ang II stimulated CYP11B2 mRNA 
expression was significantly higher in ANO1 and ANO4 vs stimulated 
VE (* P<0.05). Results are expressed as geometric mean values with 
SEM and compared using one-way ANOVA. The significance level of 
P<0.05 was considered to indicate statistical significance. 
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4.4.7.2 YFP Assay  
 
To evaluate the activity of ANO4 as CaCC, we performed an YFP assay in 
collaboration with Dr Galietta’s group.    
YFP is a quantitative screening procedure for analysis of halide cellular 
transport. Transfected cell expressing anoctamins together with a yellow 
fluorescent protein (YFP)-based halide sensor were used.   
CaCC function was assayed from the time course of cell fluorescence in 
response to extracellular addition of I− (100 mM) followed by Ionomycin, 
resulting in decreased YFP fluorescence due to CaCC-mediated I− entry.   As 
shown in Figure 4.24, [Ca2+]i elevation triggered by ionomycin caused a very 
large flow of iodide in cells expressing ANO1 and ANO2 which are CaCCs.  
ANO4’s activity is much lower although significantly higher than that of ANO5, 
which is a protein with prevalent intracellular localization (Duran, Qu, 
Osunkoya, Cui, & Hartzell, 2012) (n = 12–15 experiments, P< 0.05 vs ANO1, 
Figure 4.23). 
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Figure 4.23: Functional evaluation of ANO4 with the halide-sensitive 
(HS)- yellow fluorescent protein (YFP) assay. 
A: Representative traces of HS-YFP experiments.  B:  Anion transport 
measured with the HS-YFP assay in HEK-293 cells transfected with the 
indicated constructs. Data are shown as quenching rate (QR) 
calculated by fitting the fluorescence decay caused by extracellular 
I− addition. White bars: anion transport without intracellular 
Ca2+ elevation. Blue bars: anion transport in cells stimulated with 1 µM 
ionomycin.  Red bars: anion transport in cells stimulated with 
Ionomycin 10µM (*P< 0.05 vs ANO1).  Experiments performed at Dr 
Galietta’s laboratory.   
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4.4.7.3 XTT assay 
Because of the discrepancy between aldosterone and CYP11B2 mRNA 
results, and because of the previous literature describing an association 
between CaCCs and cell proliferation, we decided to evaluate the proliferation 
of cells transfected with ANO1, ANO4 and ANO6 plasmids, in basal or 
stimulated conditions, at XTT assay.   
The cells were seeded in 96-well plate at a density of 4x105 cells/well in 100 
µL of culture medium and transfected with Lipofectamine.  At 48 hours from 
transfection the assay was performed: cells were incubated for 2 hours at 
37°C in a CO2 incubator.  The plate was read at 450 nm in a plate reader and 
absorbance date showed as Relative Units (RU). 
At 48 hours from transfection, cell viability increased in all anoctamins, and 
the 450 nm absorbance increased from 0.28 of controls to 0.47, 0.41 and 0.42 
RU in ANO1, ANO4 and ANO6  (N=9, *P<0.05, Figure 4.24). 
 
 
 
 
Figure 4.24: Effects of Anoctamins overexpression on the viability of 
H295R cells. All three anoctamins caused an increase of cell viability 
compared to empty vector (EV). (*P<0.05). Results are expressed as 
mean values with SEM and compared using multiple t-test. The 
significance level of P<0.05 was considered to indicate statistical 
significance. 
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as the 450 nm absorbance increased from 0.32 of controls to 0.57, 0.47 and 
0.45 RU in ANO1, ANO4 and ANO6, respectively (N=9, P<0.05, Figure 4.25).  
 
 
 
 
 
Figure 4.25: Effects of ANO1, ANO4 and ANO6 overexpression on cell 
viability at baseline and in response to Ang II in H295R cells, evaluated 
at XTT assay. The increase of viability in response to AngII was bigger in 
ANO1, ANO4 and ANO6 in comparison to stimulated controls as the 450 
nm absorbance increased from 0.32 of controls to 0.57, 0.47 and 0.45 RU 
in ANO1, ANO4 and ANO6, respectively (*P<0.05). Results are expressed 
as mean values with SEM and compared using multiple t-test. The 
significance level of P<0.05 was considered to indicate statistical 
significance. 
 
 
 
 
We have also tested the effects of Ionomycin 1 µM and observed that viability 
of H295R cells increases significantly only in ANO1 transfected cells in 
comparison to treated controls, whereas it was not affected in ANO1 and 
ANO6 transfected cells (N=9, P<0.05, Figure 4.26). 
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Figure 4.26: Effect of ANO1, ANO4 and ANO6 overexpression in H295R 
on cell viability at baseline and in response to Ionomycin, as evaluated 
at XTT assay.  The viability increases significantly only in ANO1 
transfected cells in comparison to treated controls, whereas it was not 
affected in ANO1 and ANO6 transfected cells (*P<0.05). Results are 
expressed as mean values with SEM and compared using multiple t-test. 
The significance level of P<0.05 was considered to indicate statistical 
significance. 
 
 
 
 
 
Overall, the results from the comparison of ANO4 with ANO1 and ANO6 on 
their effects on aldosterone secretion and synthesis and cell proliferation in 
H295R cells in basal and stimulated conditions are synthesized in Table 4.1. 
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Table 4.1: Summary of the results of the comparison of Anoctamin 
overexpression effects on H295R cells, including a summary of the 
results from YFP assay.  Aldo: aldosterone. Proliferation is referred to 
the XTT results. NA: not available. 
 
 
From our experiments we can conclude that: 
 
1) ANO1, ANO4 and ANO6 stimulate cell proliferation in basal and AngII 
stimulated condition, although intracellular calcium increase triggered by the 
Ionomycin stimulates cell proliferation in ANO1 transfected cells only. 
2) Aldosterone secretion tends to increase in basal condition in ANO1 and 
ANO4 only. In stimulated conditions, ANO1 tends to stimulate aldosterone 
secretion while ANO4 counteract the secretagogue action. 
3) CYP11B2 mRNA expression increases was significantly higher in ANO1 
and ANO4 in baseline and AngII stimulated conditions. 
4) Only ANO1 and ANO2 generate CaCC mediated currents. ANO4 cannot 
be considered a CaCC as only at high concentrations of Ionomycin generates 
a small I- flux. 
These results suggest that ANO4 is not a CaCC. It generates small iodide 
currents in transfected HEK293 cells at YFP assay only at very high 
concentrations of Ionomycin but the fluorescence quenching curve does do 
not resemble that of classical CaCCs such as ANO1 and ANO2.  
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However, some biological effects (mainly on AngII stimulated aldosterone 
secretion and synthesis) are similar to those of ANO1. 
 
4.5 Discussion 
 
ANO4 was the third of the 7 genes up regulated in ZG vs ZF by at least >10-
fold (LGR5, VSNL1, ANO4, NEFM, VCAN, DACH1, and NR4A2).  
 
ANO4 mRNA expression was 19.9-fold higher in ZG vs ZF.  Moreover, ANO4 
resulted to be 9.3 -fold downregulated in APAs vs ZG. 
 
Microarray data were confirmed by qPCR performed on the LCM samples.  
Accordingly, IHC demonstrated that ANO4 protein was highly and selectively 
expressed in human ZG.  Its expression was mainly cytoplasmic.  
 
ANO4 is one of the members of anoctamin family, which includes 10 proteins.  
Among them, only ANO1 and ANO2 have been confirmed to be CaCC and 
contrasting data exist for the other members.  
ANO1 has a ubiquitously expression pattern, ANO2 expression appears to be 
selective for the nervous system.  They also differ in terms of sensitivity for 
[Ca2+] i, as the response threshold to its increases is higher for ANO2 than 
ANO1. 
 
CaCCs conducted currents have been observed in almost all tissues, with 
different physiological functions. CaCCs mediate the Cl− secretion in secretory 
epithelia, such as gastrointestinal, airways, salivary glands, and pancreatic 
ducts cells.   
CaCC currents have been recorded in excitable cells such as neurons, 
smooth muscles, and cardiac muscles. CaCCs are activated by [Ca2+] i, have 
an outwardly rectifying current voltage relationship and show greater current 
amplitude in a depolarization state than at hyperpolarization. 
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 ANO1 plays a role not only in the aforementioned cells in the exocrine 
function, but it regulates cell proliferation in normal tissues and tumours.  
 
ANO2 is mainly expressed in neuronal cells and can play a role in the 
synapses of olfactory cells and in hippocampus. 
ANO3 is expresses in neurons involved in nociception (Huang et al. 2013). 
ANO5 is mainly found in muscles and bones. It is not localized in the plasma 
membrane and is not a channel. Mutations in ANO5 have been found in 
gnathodiaphyseal dysplasia and muscular dystrophy (Bolduc et al. 2010). 
ANO6 is a Fas ligand-activated Cl- channel and a Ca2+ dependent scramblase 
that transports phospholipids bi-directionally between the two leaflets.  A 
mutation of ANO6 that truncates the ANO6 protein is associated with a rare 
bleeding disease, the Scott syndrome. 
 
Controversial data have been published about ANO3–10 members. Some 
authors found that  ANO3-7 are intracellular proteins with no activity as CaCC 
(Duran et al. 2012). 
On the other hand, another group has previously showed that most 
anoctamins overexpressed in the same cell line, HEK293, were expressed on 
cell membrane (Schreiber et al. 2010). 
 
It has previously been reported that ANO4, overexpressed in HEK293, 
localized at plasma membrane level and, when co-expressed with purinergic 
receptor P2Y2, it can conduct currents activated by ATP or by ionomycin. In 
particular stimulation of purinergic receptors, through an increase of [Ca2+]i, 
depolarized membrane voltages in all anoctamins transfected cells except 
ANO4, which hyperpolarized the cells. (Y Tian et al. 2012). 
 
Suzuki et al showed that ANO4 constitutively behaves as a scramblase, and 
its activity is even stronger than ANO6 with specific affinity for some 
phospholipids.  No CaCC activity was found when they measured whole cell 
current in transfected HEK293 cells.   
Duran et al. found the same result in the same cell system, where ANO4 does 
not localise on the plasma membrane, but its localisation is intracellular.  This 
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subcellular distribution of ANO4 is consistent with the lack of finding of 
chloride currents (Suzuki et al. 2013; Duran et al. 2012). 
 
Herein we report some functional studies on ANO4, which has never been 
associated to adrenal cortex endocrine function before.  
 
Functional analyses, using H295R as a model of aldosterone producing cells, 
showed that ANO4 plays a role in steroidogenesis as its overexpression and 
silencing modulate CYP11B2 mRNA levels although not accompanied to any 
change in aldosterone secretion. 
 
Stimulated aldosterone secretion by AngII or calcium agonists was instead 
affected by ANO4 overexpression as we have observed that the degree of 
aldosterone secretion in response to these drugs is lower than controls. 
 
As mentioned before, anoctamin family includes both CaCCs (such as ANO1 
and ANO2) and scramblase (such as ANO6).  In order to understand whether 
ANO4 behaves as one of the other members of its family, we have compared 
the effects of ANO1, ANO4 and ANO6 on aldosterone secretion, both basal 
and AngII stimulated. 
 
Overall, from the comparison of ANO4 with ANO1 and ANO6 we can 
conclude that the three anoctamins stimulate cell proliferation in basal and 
AngII stimulated condition, although calcium ionophore ionomycin stimulates 
cell proliferation only in ANO1 transfected cells. 
Aldosterone secretion tends to increase in basal condition in ANO1 and ANO4 
only. In stimulated conditions, ANO1 tends to stimulate aldosterone secretion 
while ANO4 counteract the secretagogue action. ANO6 did not affect 
aldosterone production. 
CYP11B2 mRNA expression increases was significantly higher in ANO1 and 
ANO4 in baseline and AngII stimulated conditions. 
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YFP assay showed that only ANO1 and ANO2 generate CaCC mediated 
currents.  ANO4 cannot be considered a CaCC as only at high concentrations 
of Ionomycin generates a small I- flux. 
These results suggest that ANO4 is unlikely to be a CaCC.  It generates small 
iodide currents in transfected HEK293 cells at YFP assay only at very high 
concentrations of Ionomycin but the fluorescence quenching curve does not 
resemble that of classical CaCCs such as ANO1 and ANO2.  
However, some biological effects (mainly on AngII stimulated aldosterone 
secretion and synthesis) are similar to those of ANO1. 
 
Consistent with the IHC findings in human ZG and kidney, 
immunofluorescence staining of ANO4-transfected cells (both HEK293 and 
H295R) showed cytoplasmic staining. This expression pattern may suggest 
that ANO4 is unlikely to be an ion channel.  It is worth to mention that the 
chloride currents recorded before in the adrenocortical cells are different from 
CaCCs. 
 
Overall, these experiments have demonstrated that ANO4, similarly to our 
previously described ZG-selective up regulated genes (NEFM, LGR5, and 
DACH1), inhibits rather than stimulates aldosterone secretion in a condition of 
[Ca2+]i increase. 
 
We have used a screening assay in HEK293 cells and did not manage to 
prove that ANO4 is a CaCC.  There are some caveats about these 
conclusions: first of all, we did not use the gold standard technique for 
detection of ion channel function, the patch-clamp. 
 
 The second consideration is that the YFP assay was performed in HEK293 
cell line whose electrophysiological properties (in terms of channels 
expression and physiological membrane potential) differ from those of the cell 
line used for the functional experiments, H295R cells.  
 
The third caveat regards the co-expression of ANO4 with receptors (such as 
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AngII or purinergic receptors) or other anoctamins, which may be necessary 
for a functional ANO4.   
Further experiments to investigate the function of ANO4 as scramblase in the 
H295R or primary cells have to be considered. 
 
In conclusion, we found that ANO4 is a novel selective ZG gene which 
negatively regulates stimulated aldosterone secretion and synthesis and a 
positively affects cell viability. It was not possible to conclusively establish a 
possible function of ANO4 in the adrenocortical cells, as we just excluded its 
function as a CaCC but did not manage to investigate other possible currents 
conducted nor scramblase activity. 
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Chapter 5: Overall discussion and perspectives 
The physiological function of aldosterone played a role in the evolutionary 
passage from aquatic to terrestrial life. The development of 
aldosterone/mineralocorticoid receptor system was necessary and functional 
to the adaptation to land life in a little salt and water environment if compared 
to the seawater (Williams 2005).  
Nowadays, excessive salt intake (9-12 g/day), a feature of the diet in most 
countries, is linked to elevated blood pressure and cardiovascular diseases.  
 
As a feature of our species, CYP11B2 expression ZG shows a patchy 
expression in human adult adrenal.  Only few cell clusters, the APCCs, are 
positive for CYP11B2, thus suggesting that the human ZG tends to produce 
less aldosterone.  Similar IHC studies in the rodent adrenal have showed that 
aldosterone synthase is expressed all over the ZG and its expression 
increases in salt-deprived conditions (Nishimoto et al., 2014).  
 
In our study, we have differentiated ZG from ZF cells by using cresyl violet 
and collected the RNA from the two layers by LCM.  Therefore, most of the 
ZG RNA was from non-APCCs cells.  
The transcriptome comparison of ZG vs ZF discovered several up regulated 
ZG genes. 
We have found that two of the top hit ZG genes, ANO4 and NEFM, inhibited 
rather than stimulate aldosterone production, ANO4 in response to 
secretagogues, NEFM by regulating dopamine suppression.   
 
Similarly, LGR5 and DACH1, the first and sixth “ZG genes” in our microarray 
assay, also inhibited aldosterone production (Shaikh et al. 2015; Zhou et al. 
2015).  
 
These results support our hypothesis that the adult human adrenal tries to 
reduce aldosterone secretion and its mineralocorticoid action as a result of 
chronic exposure to high salt from the diet. However, the effects of chronic 
salt exposure on human ZG gene expression profile will require further 
investigation. 
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Of interest, one of the top hit ZG genes investigated in this study, NEFM is 4-
fold down-regulated in ZF-like APAs carrying KCNJ5 mutations.  NEFM 
expression levels directly correlate with KCNJ5 mutational status, as 
demonstrated by transfection of mutant KCNJ5 in adrenocortical cell line 
H295R and in primary cells from ZG-like APAs highly expressing NEFM.   
These results suggest that the down-regulation of some of the ZG genes such 
as NEFM could be not only a signature of ZF-like APAs but one of the events 
necessary for the tumorigenesis of this APA subtype and give more hints 
about their cell origin.  
 
Paradoxically, KCNJ5 mutant APAs histologically and biochemically resemble 
cortisol producing ZF but, rather than from a mutant ZF cell, they are more 
likely to arise from ZG cells harbouring a mutation in KCNJ5 affecting the cell 
phenotype and gene expression profile.  
On the other hand, APCCs cells have the same mutations in CACNA1D or 
ATP1A1 genes as the small ZG-like APAs, and this observation could suggest 
that CYP11B2 positive cells in the ZG may be pre-tumorous lesions. 
 
Further investigation in terms of single cell RNA seq of KCNJ5 mutant 
transfected cells is required. 
 
In the attempt to identify the functional role of NEFM in the adrenal, we have 
observed that NEFM silencing significantly amplified aldosterone response to 
dopamine D1R agonists and antagonist.   
Dopamine is one of the main inhibitors of aldosterone secretion.  It action is 
mediated by D2R activation, with final cAMP synthesis inhibition.  D2R 
antagonist metoclopramide in fact stimulates aldosterone secretion.   
Interestingly, high sodium intake reduces aldosterone response to 
metoclopramide, and stimulates urinary dopamine excretion in normal 
individuals.   
While rat adrenal ZG expresses both D1R and D2R at mRNA and protein 
level, and is positive for specific binding sites for both receptors, the human 
ZG expresses D1-like and D2-like receptors at mRNA level (Pivonello et al. 
2004), but autoradiographic studies have identified only D2R binding sites 
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(Amenta et al. 1994). 
Here we have showed that NEFM, highly expressed in ZG, is responsible of 
the intracellular redistribution of D1R whose activation by dopamine could 
cause a stimulation rather than inhibition of aldosterone secretion.  For this 
reason, D1R is expressed but internalized, not available for dopamine 
binding, and not traceable at autoradiographic studies.  
 
Similarly to normal glomerulosa cells, small ZG-like KCNJ5 wild-type APAs 
highly expressed NEFM, as a preserved ZG feature, whereas it was 4-fold 
downregulated in KCNJ5 mutant APAs. 
This different expression levels were also correlated to different D1R staining 
pattern and different response to D1R activation: ZG-like APA cells retained 
D1R at cytoplasmic level, and fenoldopam stimulation of aldosterone in 
primary cells from this subtype was smaller than in those from KCNJ5 mutant 
APAs with membranous expression of D1R. 
 
This diversity has potential clinical implications: the measurement, in either 
peripheral or adrenal vein plasma, of aldosterone secretion in response to 
pharmacological D1R activation or blockade could be used as a diagnostic 
test to differentiate or predict the two APA subtypes. 
 
On the other hand, different responses to dopaminergic drugs have already 
been described in APAs.  Before the discovery of somatic mutations in APAs, 
differences in cellular composition had been correlated to different responses 
to D2R antagonist metoclopramide.   
Wu et al. in 1995 described that the increase of aldosterone after 
metoclopramide is inversely correlated with the percentage of ZF cells in APA. 
In other words, ZF-like APAs aldosterone secretion in response to 
metoclopramide is minor than in ZG-like APAs, thus suggesting a lower 
degree of dopaminergic inhibition (Wu et al. 1995). 
The same group found that D2R and D4R are expressed at mRNA level in 
normal ZG and that their expression in APA is inversely proportional to the 
percentage of ZF-cells (Wu et al. 2001). 
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The two APA subgroups patients present also different responses of 
aldosterone secretion to metoclopramide on changes of salt intake: a 
subgroup with less dopaminergic inhibition and less urinary dopamine 
excretion and greater BP elevation on high salt diet (Wu et al. 2002). 
 
Here we postulate that KCNJ5 mutant ZF-like APAs have a D1R/D2R 
imbalance, due not only to the previously reported D2R down-regulation but 
also to the D1R localisation at plasma membrane level.   
The consequences of different mutations are not only on the cellular 
composition but also on responsiveness to dopaminergic drugs. 
 
ANO4 was the second gene subject of this PhD. A member of anoctamin 
family, ANO4 is a novel selective ZG gene. It differs from NEFM as its 
expression in APAs does not differ from ZF and is not affected by APA 
genotype and subtype. 
We found that ANO4 negatively regulates stimulated aldosterone secretion 
and regulates cell proliferation. An intracellular protein, it did not conduct 
currents at YFP thus excluding a function as CaCC.  
It generates small iodide currents, and only at very high concentrations of 
Ionomycin, in transfected HEK293 cells as detected by YFP assay, but the 
fluorescence quenching curve does do not resemble that of classical CaCCs 
such as ANO1 and ANO2.  
The comparison of ANO4 with ANO1 and ANO6 effects on basal and 
stimulated aldosterone secretion and cell proliferation found that all of them 
stimulate cell proliferation in basal conditions and following AngII stimulation. 
Aldosterone secretion tends to increase in basal condition in ANO1 and ANO4 
only. In stimulated conditions, ANO1 tends to stimulate aldosterone secretion 
while ANO4 counteract the secretagogue action. 
These results suggest that ANO4 is unlikely to be a CaCC.  However, some 
biological effects (mainly on AngII stimulated aldosterone secretion and 
synthesis) are similar to those of ANO1. 
 
Although we did not manage to conclusively determine its function in the 
adrenocortical cells, ANO4 negative regulation of steroidogenesis is 
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consistent with that found for other ZG selective genes, including NEFM, 
found at our microarray study (Shaikh et al., 2015; Zhou et al., 2015). 
 
Our studies present several limitations. First of all, the adrenal samples used 
for the collection of RNA do not include completely normal adrenals, but are 
from APAs and Phaeocromocytoma patients, the latter included as they in a 
sense represent the opposite spectrum to PA patients in terms of sodium 
balance. 
 
Second, the immortalized adrenal cell line, H295R, is not a perfect model for 
native ZG cells.  H295R cells were derived from a human adrenal carcinoma 
and secrete androgens and cortisol besides aldosterone (Wang et al. 2012). 
We have therefore for selected experiments supported the cell line data with 
data from primary human adrenal cells from ZG and ZF-like APAs.  
Future improvements to the study could be done by culturing separately ZG 
and ZF cells or from an immortalized cell line derived from these layers to be 
used to silence or overexpress genes in primary cells.  The absence of an 
animal model of APA affects the choice of models to be used to investigate 
these genes.  
 
In summary, two novel genes appeared to be up-regulated in ZG vs ZF as the 
result of a whole transcriptome comparison of pathological (APAs) and 
physiological (adjacent ZG) sites for aldosterone production and of ZG with 
paired cortisol producing ZF.  
 
In addition, we have found that ANO4 and NEFM, genes highly up-regulated 
in human ZG, inhibit aldosterone secretion, the first in response to 
secretagogues, the second as part of dopamine inhibition, since it affects 
dopamine receptor D1R trafficking in human ZG and in ZG-like APAs.  
 
The two APA subtypes’ heterogeneity can be explained by genotype, 
biochemical and transcriptome differences. NEFM downregulation in KCNJ5 
mutant APAs is an example of this diversity, which has potential clinical, 
translational consequences. 
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The inhibitory effects of ZG up-regulated genes on aldosterone production 
may represent an attempt to respond to chronic high salt intake action on the 
cardiovascular and renal system. 
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List of publications and conference papers following my work during the 
PhD 
 
In Italics the publications I am co-author of, but which are not part of my PhD 
projects. 
 
• Neurofilament Medium Polypeptide (NEFM), a marker for Zona 
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Mediated Secretion of Aldosterone Maniero C, Garg S, Zhao W, Johnson 
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